Study Protocol O-icial Title:  A Single-Center, Open Label, Phase 4 Study of the Safety and E-icacy of Fixed combination Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution (MydCombi®) Administered with the MydCombi Dispenser for Pupil Dilation (The MIST 2.1 Study)      NCT Number 06217796   Date of Document:  23 October 2023 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A     
 
CONFIDENTIAL   
FINAL -A 23 OCTOBER  2023 
   
 
   
 
 
PROTOCOL EYN-MYD-TP-41 
VERSION A 
 
 
A SINGLE-CENTER, OPEN LABEL, PHASE 4 STUDY OF THE SAFETY AND EFFICACY OF 
FIXED COMBINATION PHENYLEPHRINE 2.5%-TROPICAMIDE 1% OPHTHALMIC 
SOLUTION (MYDCOMBI®) ADMINISTERED WITH THE MYDCOMBI DISPENSER FOR 
PUPIL DILATION 
(THE MIST-2.1 STUDY) 
 
 
 
 
SPONSOR: 
 
EYENOVIA, INC. 
295 MADISON AVENUE, SUITE 2400 
NEW YORK NY  10017 
USA 
PHONE:  833-393-6684 
 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A     
 
CONFIDENTIAL  - PAGE 2 OF 54 
FINAL -A 23 OCTOBER 2023 
 TABLE OF CONTENTS 
 
LIST OF ABBREVIATIONS ......................................................................................................... ....... 5 
1. PERSONNEL AND FACILITIES ............................................................................................... 6  
2. STUDY SY NOPSIS ............................................................................................................. .......... 7 
2.1. Study Objective .......................................................................................................... ................ 7  
2.2. Study Drugs .............................................................................................................. .................. 7  
2.3. Study Population ......................................................................................................... ............... 7  
2.4. Study Design ............................................................................................................. .................. 7  
2.5. Inclusio n Criteria ....................................................................................................... ................ 7  
2.6. Exclusio n Criteria ....................................................................................................... ............... 8  
2.7. Primary Performance Endpoint ............................................................................................. .. 8 
2.8. Exploratory Outcomes ..................................................................................................... .......... 9  
2.9. Safety Outcomes .......................................................................................................... ............... 9  
2.10. Schedule of Visits, Pro cedures and Evaluations .................................................................. 10  
2.10.1. Study Medication Administration and Clinical Assessments ..................................... 10  
3. INTRODUCTION AND RATIONALE ..................................................................................... 11  
3.1. Introduction ............................................................................................................. ................. 11  
3.2. Pupil Dilation ........................................................................................................... ................. 11  
4. INVESTIGATIONAL PRODUCT DESCRIPTION ................................................................ 13  
4.1. Findings from Non-Clinical and Clinical Studies .................................................................. 13  
4.2. How Provided ............................................................................................................. .............. 13  
4.3. Route of Administration, Dosage, Regimen, Treatment Period(s) ...................................... 13  
5. STUDY OBJECTIVE ............................................................................................................ ...... 13 
6. STUDY DESIGN................................................................................................................ .......... 13 
7. STUDY OUTCOMES ............................................................................................................. ......... 14 
7.1. Effectiveness Outcomes ................................................................................................... ........ 14  
7.2. Safety Outcomes .......................................................................................................... ............. 14  
8. STUDY POPULATION ........................................................................................................... ... 15 
8.1. Inclusio n Criteria ....................................................................................................... .............. 15  
8.2. Exclusio n Criteria ....................................................................................................... ............. 15  
9. STUDY ME THODS .............................................................................................................. ...... 16 
9.1. Subject Informed Consent ................................................................................................. ...... 16  
9.2. Subject Selection and Screening Procedures ......................................................................... 16  
9.3. Randomization to Study Drug Administration Sequence .................................................... 16  
9.4. Study Drug Packaging, Labeling and Storage ....................................................................... 17  
9.5. Study Drug Administration ................................................................................................ ..... 17  
9.6. Study Visits and Clinical Assessments ................................................................................... 17 
9.6.1. Screening Visit (-7 Days to Day 0) ................................................................................... 1 7 
9.6.2. Treatment Visit (Day 0) ................................................................................................ .... 17  
9.6.3. Unschedul ed Visits ..................................................................................................... ....... 19  
9.6.4. Missed Visits .......................................................................................................... ............ 19  
9.7. Study Exit ............................................................................................................... ................... 19  
9.7.1. Subject Termination .................................................................................................... ..... 19  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A     
 
CONFIDENTIAL  - PAGE 3 OF 54 
FINAL -A 23 OCTOBER 2023 
 9.7.2. Subject Completion ..................................................................................................... ...... 19  
10. ADVERSE EVENTS ............................................................................................................ ....... 20 
10.1. Adverse Event Definitions ............................................................................................... ...... 20  
10.1.1. Adverse Event (AE) .................................................................................................... .... 20  
10.1.2. Adverse Drug Reaction (ADR) ...................................................................................... 20  
10.1.3. Unexpected Adverse Event or Unex pected Suspected Adverse Reaction .................. 20  
10.1.4. Suspected Adverse Reaction .......................................................................................... 2 0 
10.1.5. Life-Threatening Adverse Event or Life -Threatening Suspected Adverse Reaction 21  
10.1.6. Serious Adverse Event (SAE) or Serious Suspected Adverse Reaction ..................... 21  
10.1.7. Treatment-Emergent Adverse Event (TEAE) .............................................................. 21  
10.2. Adverse Event Assessment and Documentation .................................................................. 22  
10.2.1. Adverse Event Severity................................................................................................. .. 22 
10.2.2. Adverse Event Relationship to Study Drug .................................................................. 23  
10.3.  Adverse Event Reporting ................................................................................................. . 23 
10.3.1.  Expedited Adverse Event Reporting ....................................................................... 24  
10.4.  Device Deficiency Reporting .............................................................................................  24 
11. STATISTICAL METHODS .......................................................................................................  2 4  
11.1. Efficacy Endpoints ...................................................................................................... ........... 24  
11.2. Sample Size ............................................................................................................. ................ 25  
11.3. Safety Outcomes ......................................................................................................... ............ 25  
11.4. Analysis Populations .................................................................................................... .......... 25  
11.4.1. Intent to Treat Population ............................................................................................ . 25 
11.4.2. Per Protocol Population ............................................................................................... .. 25 
11.4.3. Safety Population ..................................................................................................... ....... 26  
11.5. General Statisti cal Considerations ...................................................................................... . 26 
11.5.1. Analysis of Primary Efficacy ......................................................................................... 26 
11.5.2. Additional Efficacy Analyses ......................................................................................... 26 
11.5.3. Interim Analyses ...................................................................................................... ....... 26  
11.5.4. Analysis of Baseline Data ............................................................................................. .. 26 
12. QUALITY ASSURANCE A ND QUALITY CONTROL ............................................................ 27  
12.1. Study Monitoring ........................................................................................................ ........... 27  
12.2. Study Product Accountability ............................................................................................ ... 27  
13. ETHICAL AND REGULATORY  CONSIDERATIONS ........................................................... 28  
13.1. Institutional Review .................................................................................................... ........... 28  
13.2. Informed Consent ........................................................................................................ ........... 28  
13.3. Subject Confidentiality ................................................................................................. ......... 28  
14. DATA HANDLING AND RE CORD KEEPING ......................................................................... 29  
14.1. Data Quality Control and Reporting .................................................................................... 2 9 
14.2. Data Archiving .......................................................................................................... ............. 29  
14.3. Records Retention ....................................................................................................... ........... 29  
14.4. Protocol Amendmen ts ..................................................................................................... ....... 29  
15. REFERENCES ................................................................................................................ ............... 30 
APPENDIX 1:  SCHEDULE OF MEDICATIO N ADMINISTRATION AND EXAMS ............... 32  
APPENDIX 2:  Mydcom bi Approved label ....................................................................................... 33  
APPENDIX 3:  EXAMINAT ION PROCEDURES ........................................................................... 43  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A     
 
CONFIDENTIAL  - PAGE 4 OF 54 
FINAL -A 23 OCTOBER 2023 
 APPENDIX 4:  SPONSOR AND INVE STIGATOR OBLIGATIONS ........................................... 46  
APPENDIX 5:  WORLD MEDICAL ASSOCIAT ION DECLARATION OF HELSINKI .......... 49  
 
  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A     
 
CONFIDENTIAL  - PAGE 5 OF 54 
FINAL -A 23 OCTOBER 2023 
 LIST OF ABBREVIATIONS 
 
Abbreviation Term 
AC Anterior chamber 
AE  Adverse event 
ADR Adverse drug reaction 
AT Artificial tears 
CF Count fingers 
CFR Code of Federal Regulations 
DVA Distance Visual Acuity 
eCRF Electronic case report form 
ETDRS Early Treatment Diabe tic Retinopathy Study (Chart) 
FDA United States Food and Drug Administration 
GCP Good Clinical Practice 
HM Hand motion 
IB Investigator brochure 
ICF Informed consent form 
ICH International Conference on Harmonization 
IND Investigational New Drug 
IOL Intraocular lens 
IOP Intraocular pressure 
IRB Institutional Review Board 
ITT Intent-to-treat  
LP Light perception 
NLP No light perception 
OU Both eyes (within this protocol, OU does not  connote simultaneous treatment/evaluation) 
PETG Polyethylene terephthalate glycol 
PP Per-protocol 
SAE Serious adverse event 
SD Standard deviation 
SLE Slit lamp examination 
TEAE Treatment-emergent adverse event 
TLR Total letters read 
UCDVA Uncorrected distance visual acuity 
US United States 
VA Visual acuity 
WMA World Medical Association 
µD Microdose 
µL Microliter 
NOTE:  The first occurrence of some abbreviations is  not spelled out in the document (e.g., units of 
measure). 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 6 OF 54 
FINAL -A 23 OCTOBER 2023 
  
PROTOCOL EYN-MYD-TP-41 
VERSION A 
 
 
A SINGLE-CENTER, OPEN LABEL, PHASE 4 STUDY OF THE SAFETY AND EFFICACY OF 
FIXED COMBINATION PHENYLEPHRINE 2.5%-TROPICAMIDE 1% OPHTHALMIC 
SOLUTION (MYDCOMBI)®) ADMINISTERED WITH THE MYDCOMBI DISPENSER FOR 
PUPIL DILATION 
(THE MIST-2.1 STUDY) 
 
 
1. PERSONNEL AND FACILITIES 
 
Study Sponsor: Eyenovia, Inc. 
295 Madison Avenue, Suite 2400 
New York, NY  10017  USA 
Phone:  833-393-6684 
Email:  admin@eyenovia.com  
 
Medical Monitor: Andrea Le, Senior Director Pharmacovigilance & Safety 
Phone: 415-629-1139 
Email: ale@eyenovia.com  
 
Clinical Study Manager: Kristi Patterson, Se nior Clinical Trial Manager, Clinical 
Operations 
Phone: 650-504-2005 
Email: kpatterson@eyenovia.com   
 
Clinical Data Manager: Lucinda Marinus , Director, Clinical Data Management 
Phone:  949-903-4325 
Email:  lmarinus@eyenovia.com  
 
Overall Program Management: Greg Benne tt, VP, Clinical Program Strategy and 
Development 
Phone:  650-504-2005 
Email:  gbennett@eyenovia.com   
 
  
 
 
  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 7 OF 54 
FINAL -A 23 OCTOBER 2023 
 2. STUDY SYNOPSIS 
 
2.1. Study Objective    
 
The primary objective of this study is to ev aluate the safety and efficacy of MydCombi® (phenylephrine 
2.5%-tropicamide 1% ophthalmic solution) when dosed with 1 spray per eye with the MydCombi dispenser 
for pupil dilation. 
 
2.2. Study Drugs 
 
 Product, Dosage and Mode of Administration:   Commercially available MydCombi (Fixed 
combination ophthalmic solution - phenylephrine 2.5%-tropicamide 1%) administered as one spray 
per eye with the MydCombi dispenser. 
 
2.3. Study Population  
 
Up to 30 volunteer participants will be enrolled at  a single study site in the United States (US) and a 
minimum of 25 subjects will receive study drug administ ration at the Treatment Visit in order to complete 
follow-up on 25 subjects.   
 
2.4. Study Design   
 
This trial is a single-center, open label study evaluatin g 1 spray per eye with the MydCombi dispenser, to 
provide adequate dilation to allow visualization of th e back of the eye during a routine eye examination. 
 
Volunteer participants will be screened for study elig ibility during a Screening Visit and enrolled after 
signing the study-specific informed consent form (ICF).  Subjects meeting all eligibility criteria may proceed 
to the Treatment Visit on the same day (Day 0) and screening values will be used for baseline.  If the 
treatment visit is scheduled on a separate date, baselin e measurements will be taken, then a single spray of 
MydCombi will be administered to each eye (OU).  Afterwards, efficacy and sa fety assessments will be 
performed.   
 
2.5. Inclusion Criteria 
 
Subjects eligible for study participation must meet each  criterion listed below.  Ocular criteria must be met 
for both eyes. 
  
1. Male or female ≥ 18 years of age 
2. Female subjects must be either 1-year postm enopausal, surgically sterilized, or, if of 
childbearing potential, have a negative urine pre gnancy test during the Screening Visit and agree 
to use an acceptable form of contraception throughout the study.  Acceptable methods include 
the use of at least one of the following: intrauterine (intrauterine device), hormonal (oral, 
injection, patch, implant, ring), barrier w ith spermicide (condom, diaphragm), or abstinence.  
3. Ability to provide signed written consent prior to pa rticipation in any study-related procedures.   
4. Ability to return for the study treatment visit. 
5. Photopic screening pupil diameter ≤ 3.5 mm in each eye. 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 8 OF 54 
FINAL -A 23 OCTOBER 2023 
  
2.6. Exclusion Criteria 
 
Subjects with any of the following diseases, surgeries or conditions are ineligible for study participation.  
Subjects may not participate if either eye m eets any of the ocular exclusion criteria. 
 
1. Pregnancy or lactation. 
2. Allergy to phenylephrine hydrochloride. 
3. Allergy to tropicamide. 
4. Allergy to benzalkonium chloride. 
5. History of benign prostatic hyperplasia. 
6. Participation in any study of an investigational drug or device within 30 days prior to the 
Screening Visit, or at any time during the study period. 
7. History of closed-angle glaucoma. 
8. Anatomically narrow anterior chamber angles (Van Herrick grade ≤ 2 in either eye). 
9. Ocular surgery or laser treatment of any kind prior to the Screening Visit. 
10. History of chronic or acute uveitis. 
11. History of traumatic iritis or hyphema. 
12. History of traumatic mydriasis or angle recession. 
13. History of heterochromia. 
14. Irregularly shaped pupil secondary to oc ular trauma or congenital defect. 
15. History of neurogenic pupil disorder (e.g., Horne r’s syndrome, third cranial nerve palsy, Adie’s 
pupil, Argyl Robertson syndrome, etc.). 
16. History of anterior chamber intraocu lar lens (IOL) or iris-fixated IOL. 
17. History of iris surgery of any kind (e.g ., iridotomy, iridectomy, coreoplasty). 
18. History of iris atrophy. 
19. History of iris – cornea apposition/touch. 
20. Unwilling or unable to discontinue use of contact lenses at the treatment visit. 
21. Use of cholinergic agonists (varenicline, cevim eline, pilocarpine), ophthalmic cholinesterase 
inhibitors (isoflurophate, deme carium, physostigmine) and or a ny agent that may exaggerate 
the pressor effects of atropine-like drugs (phenylephrine, atropine). 
22. Current active eye disease for which topical or systemic ophthalmic medication is necessary, 
except for dry eye disease managed using artificial tears (AT).   AT’s must be discontinued 
on the day of the treatment visit. 
23. Presence of a severe/serious ocular condition, or any other unstable medical condition that, in the 
Investigator’s opinion, may preclude study treatment and/or follow-up. 
 
2.7. Primary Performance Endpoint 
 
The primary performance endpoint is the mean change in pupil diameter at 30 minutes from the time of drug 
dose versus baseline, as measured by digital pupillom etry in highly photopic conditions.  The highly 
photopic condition will be established using a fully-charg ed transilluminator (muscle light) at the brightest 
setting.   
 
 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 9 OF 54 
FINAL -A 23 OCTOBER 2023 
 2.8. Exploratory Outcomes 
 
 Proportion of eyes achieving pupil diameter of 6.0 mm or greater at 30 minutes 
 Proportion of eyes achieving pupil diameter of 7.0 mm or greater at 30 minutes 
 Mean change in pupil diameter at other timepoints (15, 60, 90, 150, 210 and 360 minutes) 
 Distribution of pupil diameters at 15, 30, 60, 90, 150, 210 and 360 minutes 
 Time from baseline to maximal pupil dilation 
 Time from treatment time 0 to pupil size ≤ baseline 
 
These exploratory outcomes will also be measured using digital pupillometry in highly photopic conditions. 
 
2.9. Safety Outcomes 
 
 Slit-lamp examination findings 
 Occurrence of AEs 
 Visual acuity changes 
  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 10 OF 54 
FINAL -A 23 OCTOBER 2023 
 2.10.  Schedule of Visits, Procedures and Evaluations 
 
The study includes a Screening Visit, which must occur between 0 and 7 days prior to treatment; followed by 
the Treatment Visit.  The Treatment Visit must occur between Day 0 (Screening Visit) and 7 days following 
the Screening Visit.  The study visit schedule is  presented in flow chart form in Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  Study Visit Flow Chart 
 
 
2.10.1.  Study Medication Administration and Clinical Assessments 
 
Study medication administration and clinical assessment s will be performed at study visits as shown in 
APPENDIX 1:  SCHEDULE OF MEDICATION ADMINISTRATION AND EXAMS. Screening 
Visit 
Treatment Visit  
MydCombi  administered 
Efficacy & Safety assessments -7 Days to 0 Days prior to the Treatment 
Visit 
Study Exit Fails to meet 
inclusion/exclusion criteria 
Meets eligibility criteria 
0 - 7 Days after the Screening Visit 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 11 OF 54 
FINAL -A 23 OCTOBER 2023 
 3. INTRODUCTION AND RATIONALE  
  
3.1. Introduction 
 
 
MydCombi (fixed combination phenylephrine 2.5%-tr opicamide 1%) is a proprietary product administered 
via the MydCombi dispenser to facilitate accurate t opical ocular delivery of a controlled quantity of 
mydriatic agents in a precise manner to maximize ther apeutic control and minimize systemic absorption and 
loss to washout.  In the Phase 3 studies, the dose tested was 2 administrations given 5 minutes apart.   
 
Eyenovia, the Sponsor of this study, received approv al for MydCombi in May 2023.  This approval was 
based upon Eyenovia studies EYN-MYD-TP-31 and EYN-MYD-TP-32.  This approval included the labeling 
requirement that 2 sprays were required for dilation.  
 
 
3.2. Pupil Dilation 
 
A variety of ophthalmic evaluations require pupil dilation to provide an unobstructed view of the lens, retina, 
and optic nerve. The degree of pupil dilation required depends on the procedure being performed.   For 
routine diagnostic procedures, and in conditions where short term pupil dilation is desired, the goal is to 
achieve adequate mydriasis for visualization with mi nimal cycloplegic effect. MydCombi was approved in 
May 2023 for this use. 
 
As shown in Figure 2,  the Eyenovia MydCombi dispen ser is designed to deliver a finely controlled 
microdroplet spray of phenylephrine 2.5%-tropicamid e 1% ophthalmic solution with precisely defined 
volume, velocity, and geometry.1 These characteristics facilitate high-pr ecision, piezo-generated medication 
delivery that gently coats the ocular surface. 
 
 
1 Ianchulev T, Chayet A, Kahook M, Packer M, Pasquale L,  Weinreb RN. Pharmacodynamic profile of mydriatic agents 
delivered by ocular piezo-ejection microdosing compared w ith conventional eyedropper. Ther Deliv. 2016;7(11):751-
760. 
 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 12 OF 54 
FINAL -A 23 OCTOBER 2023 
  
 
Figure 2: Microdroplet Di stribution Pattern from the Mydcombi Dispenser 
Image analysis of high-speed photographs of the microdroplet plume quantitatively confirms precise 
medication microdroplet delivery. Shown are representative side (A) and cross-sectional (B) views of the 
droplet dispersal pattern. Color-coding indicates the percentage of the total medication dose present at 
different distances from the nozzle-to-target dead- cent er axis. The cross-sectional pattern on the right was 
captured 3 cm from the Mydcombi dispenser nozzle. 
 
  

PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 13 OF 54 
FINAL -A 23 OCTOBER 2023 
 4. INVESTIGATIONAL PRODUCT DESCRIPTION 
 
This study will evaluate the safety and efficacy of  MydCombi (phenylephrin e 2.5%-tropicamide 1% 
ophthalmic solution) dosed as 1 spray per eye for m ydriasis in routine diagnostic procedures and in 
conditions where short-term pupil dilation is desired. 
 
4.1. Findings from Non-Clinical and Clinical Studies  
 
The approved labeling is included as Appendix 2. 
4.2. How Provided 
Commercially available MydCombi will be provided in  the MydCombi dispenser.  Details are included in 
the approved label provided as Appendix 2. 
 
4.3. Route of Administration, Dosage, Regimen, Treatment Period(s) 
The study medication will be administered in accord ance with FDA approved labeling with the exception 
that a single spray will be administered as opposed to the currently approved 2 sprays.  
 
5. STUDY OBJECTIVE 
 
The primary objective of this study is to evaluate the safety and efficacy of one spray of Eyenovia’s fixed 
combination of phenylephrine 2.5%-tropi camide 1% ophthalmic solution (MydCombi®) for pupil dilation. 
 
 
6. STUDY DESIGN 
 
This trial is a single-center, open label study evalua ting 1 spray of MydCombi, for mydriasis in routine 
diagnostic procedures and in conditions wher e short-term pupil dilation is desired. 
 
Volunteer participants will be screened for study elig ibility during a Screening Visit and enrolled after 
signing the study-specific informed consent form (ICF). Subjects meeting all eligibility criteria may proceed 
to the Treatment Visit on the same day (Day 0) and screening values will be used for baseline.  If the 
treatment visit is scheduled on a separate date baseline measurements will be taken, then a single spray of 
MydCombi will be administered to both eyes (OU).  Afterwards, efficacy and safety assessments will be 
performed.   
 
 
 
  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 14 OF 54 
FINAL -A 23 OCTOBER 2023 
 7. STUDY OUTCOMES 
 
7.1. Effectiveness Outcomes 
 
The primary performance endpoint is mean change in  pupil diameter at 30 minutes from the time of first 
drug dose versus baseline, as measured by digital p upillometry in highly photopic conditions.  The highly 
photopic condition will be established using a fully-charg ed transilluminator (muscle light) at the brightest 
setting.   
 
The curve of the mean change in p upil diameter will be defined for a single spray of MydCombi, Eyenovia’s 
fixed combination phenylephrine 2.5%-tropicamide 1%.   
 
The study’s sample size will provide data to generate descriptive statistics for the dilation curve for 1 spray 
of MydCombi.  No other formal analyses are planned. 
 
Additional exploratory outcomes (also to be measured in highl y photopic conditions) include: 
 
 Proportion of eyes achieving pupil diameter of 6.0 mm or greater at 30 minutes 
 Proportion of eyes achieving pupil diameter of 7.0 mm or greater at 30 minutes 
 Mean change in pupil diameter at other timepoints (15, 30, 60, 90, 150, 210 and 360 minutes) 
 Distribution of pupil diameters at 15, 30, 60, 90, 150, 210 and 360 minutes 
 Time from baseline to maximal pupil dilation 
 Time from treatment time 0 to pupil size ≤ baseline 
 
7.2. Safety Outcomes  
 
All safety information will be collected and summarized  for a single spray of MydCombi (fixed combination 
of phenylephrine 2.5%-tropicamide 1%) for the following outcomes: 
 
 Slit-lamp examination (SLE) findings 
 Occurrence of AEs 
 Visual acuity changes 
  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 15 OF 54 
FINAL -A 23 OCTOBER 2023 
 8. STUDY POPULATION   
 
Up to 30 volunteer participants will be enrolled at  a single study site in the United States (US) and a 
minimum of 25 subjects will be receive study drug administ ration at the Treatment Visit in order to complete 
follow-up on 25 subjects. 
 
8.1. Inclusion Criteria 
 
Subjects eligible for study participation must meet each  criterion listed below.  Ocular criteria must be met 
for both eyes. 
  
1. Male or female ≥ 18 years of age. 
2. Female subjects must be either 1-year postm enopausal, surgically sterilized, or, if of 
childbearing potential, have a negative urine pre gnancy test during the Screening Visit and agree 
to use an acceptable form of contraception throughout the study.  Acceptable methods include 
the use of at least one of the following: intrauterine (intrauterine device), hormonal (oral, 
injection, patch, implant, ring), barrier w ith spermicide (condom, diaphragm), or abstinence.  
3. Ability to provide signed written consent prior to pa rticipation in any study-related procedures.   
4. Ability to return for the study treatment visit. 
5. Photopic screening pupil diameter ≤ 3.5 mm in each eye. 
 
8.2. Exclusion Criteria 
 
Subjects with any of the following diseases, surgeries or conditions are ineligible for study participation.  
Subjects may not participate if either eye m eets any of the ocular exclusion criteria. 
 
1. Pregnancy or lactation. 
2. Allergy to phenylephrine hydrochloride. 
3. Allergy to tropicamide. 
4. Allergy to benzalkonium chloride. 
5. History of benign prostatic hyperplasia. 
6. Participation in any study of an investigational drug or device within 30 days prior to the 
Screening Visit, or at any time during the study period. 
7. History of closed-angle glaucoma. 
8. Anatomically narrow anterior chamber angles (Van Herrick grade ≤ 2 in either eye). 
9. Ocular surgery or laser treatment of any kind prior to the Screening Visit. 
10. History of chronic or acute uveitis. 
11. History of traumatic iritis or hyphema. 
12. History of traumatic mydriasis or angle recession. 
13. History of heterochromia. 
14. Irregularly-shaped pupil secondary to oc ular trauma or congenital defect. 
15. History of neurogenic pupil disorder (e.g., Horne r’s syndrome, third cranial nerve palsy, Adie’s 
pupil, Argyl Robertson syndrome, etc.). 
16. History of anterior chamber intraocu lar lens (IOL) or iris-fixated IOL. 
17. History of iris surgery of any kind (e.g ., iridotomy, iridectomy, coreoplasty). 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 16 OF 54 
FINAL -A 23 OCTOBER 2023 
 18. History of iris atrophy. 
19. History of iris – cornea apposition/touch. 
20. Unwilling or unable to discontinue use of contact lenses at treatment visits. 
21. Use of cholinergic agonists (varenicline, cevimeline, pilocarpine), ophthalmic cholinesterase 
inhibitors (isoflurophate, deme carium, physostigmine) and or any agent that may exaggerate the 
pressor effects of atropine-like drugs (phenylephrine, atropine). 
22. Current active eye disease for which topical or systemic ophthalmic medication is necessary, 
except for dry eye disease managed using artificial tears (AT).   AT’s must be discontinued on 
the day of the treatment visit. 
23. Presence of a severe/serious ocular condition, or any other unstable medical condition that, in the 
Investigator’s opinion, may preclude study treatment and/or follow-up. 
 
9. STUDY METHODS 
 
9.1. Subject Informed Consent 
 
The IRB-approved study ICF must be used for administration of informed consent.   
 
The investigator or designee will explain the study purpose, procedures and responsibilities to the potential 
participant and provide sufficient opportunity to  ask questions, while allowing adequate time for 
consideration of the information provided.  Written con sent for study participation must be present prior to 
initiation of any study-specific procedure; subjects w ill be considered enrolled in the study upon their 
signature on the consent form(s).  It is the responsibility of the Investigator to complete the informed consent 
process, maintain a copy of the signed consent form in the subject’s medical records, and provide each 
subject with a copy of their fully-executed consent documents. 
 
9.2. Subject Selection and Screening Procedures 
 
Study participants will be recruited from the Investigat or’s patient population, referrals, or other outreach 
methods.  Written recruitment materials directed to poten tial study participants must be approved by the IRB.   
 
Where possible, candidate participants may be pre-screened via review of their medical charts to evaluate 
potential eligibility based on study inclusion/exclusion cr iteria.  During the informed consent discussion, the 
potential participant’s willingness and ability to meet the follow-up requirements will be evaluated.  Those 
who elect to sign the study consent form(s) will be considered enrolled in the study and given a study 
identification code.   At/after the time of enrollment, the subject will be evaluated at the Screening Visit for 
study eligibility based on eligibility requirements established in Sections 8.1  and 8.2.  Subjects who fail to 
qualify for the study will be considered “screen fa ilures” and exited from the study.  Subjects who 
successfully complete the Screening Vi sit will continue to the Treatment portion of the visit or be scheduled 
for their Treatment Visit at which the study medication will be administered.   
 
9.3. Randomization to Study Drug Administration Sequence  
 
As the study is open label, this section is not applicable.  
 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 17 OF 54 
FINAL -A 23 OCTOBER 2023 
 9.4. Study Drug Packaging, Labeling and Storage 
 
Commercial MydCombi product will be provided for use in the study. 
 
9.5. Study Drug Administration 
 
Site personnel designated to administer study medication will be trained by the Sponsor on proper use of the 
MydCombi dispenser prior to study initiation.  Comme rcial MydCombi will be used for drug administration 
for all subjects.  Subjects will be administered 1 spray of study drug in each eye.   
Study drug administration procedures are further detailed in APPENDIX 2:  Mydcombi Approved label 
 
Site personnel should confirm the spray was felt on the cornea.  If the subject cannot confirm feeling the 
spray or the spray is visible on the lid of the eye, a second spray may be administered.  The number of sprays 
will be recorded for each eye.  
 
9.6. Study Visits and Clinical Assessments 
 
Study participants will be evaluated at a Screening Visit.  Subjects who qualify for further study participation 
will continue to the treatment portion of the visit or be scheduled for the Treatment Visit at which the study 
drug is administered, and examinations are performed.  Data collected will be documented in the source 
records and recorded on study electronic Case Report Forms (eCRF).   
 
The timing and frequency of assessments/pro cedures to be performed is outlined in  
APPENDIX 1:  SCHEDULE OF MEDICATION ADMINISTRATION AND EXAMS.   Methodology 
for study examinations is presented in APPENDIX 3: EXAMINATION PROCEDURES .APPENDIX  3:  
EXAMINATION PROCEDURES . 
 
9.6.1.  Screening Visit (-7 Days to Day 0) 
 
The Screening Visit must occur no more than 7 days prior and no less than 0 days prior to the Treatment 
Visit.  At the Screening Visit, the following activities will be performed:  
 
 Documentation of study informed consent using IRB-approved consent form(s) 
 Collection of demographic data (gender, age, ocular comorbidities) 
 Collection of medical/ocular history and medication use data 
 Administration of urine pregnancy test, if applicable 
 DVA using habitual correction – OU 
 Pupil diameter measurement – OU 
 Slit lamp biomicroscopy – OU 
 IOP measurement - OU  
 Pupillary light reflex - OU  
 Iris Color 
 Determination of study eligibility 
 
9.6.2.  Treatment Visit (Day 0) 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 18 OF 54 
FINAL -A 23 OCTOBER 2023 
  
Subjects may be screened and treated on the same day,  however screening may occur no more than 7 days 
prior to treatment.  If screening is not on the same day as treatment, the subject will be queried regarding the 
occurrence of any adverse events since the time of the Screening Visit.  If the screening and Treatment visit 
are conducted on the same day, the screening values may be used for the baseline values.  The subject will be 
treated after the following baseline measurements will be  taken prior to study drug administration.  (For 
subjects whose Screening and Treatment Day are on the same day, these tests do not need to be repeated.) 
  
 Pupil diameter measurement – OU 
 Pupillary light reflex - OU 
 DVA using habitual correction– OU 
 Slit lamp biomicroscopy – OU 
 IOP measurement - OU  
 AE assessment  
 
The study drug will be administered as a single sp ray OU. The completion of the administration of 
medication in the subject’s second eye will be consider ed Time 0 (T0).  The following assessments will be 
done at the timepoints specified below: 
 
Timepoint Clinical Assessment (to be performed in the 
specified order) 
Time 1: T0 + 15 minutes (+/- 2 minutes)  Pupil diameter measurement – OU 
Time 2: T0 + 30 minutes (+/- 5 minutes)  Pupil diameter measurement – OU 
 Pupillary light reflex - OU 
Time 3: T0 + 60 minutes (+/- 5 minutes)  Pupil diameter measurement – OU 
Time 4: T0 + 90 minutes (+/- 5 minutes)  Pupil diameter measurement – OU 
 Pupillary light reflex - OU 
  IOP measurement – OU 
Time 5: T0 + 150 minutes (+/-10 minutes)  Pupil diameter measurement – OU 
Time 6: T0 + 210 minutes (+/-10 minutes)  Pupil diameter measurement – OU 
Time 7: T0 + 360 minutes (+/-30 minutes)  Pupil diameter measurement – OU 
 Pupillary light reflex - OU 
 DVA using habitual correction – OU 
 Slit lamp biomicroscopy – OU 
 AE assessment 
 
  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 19 OF 54 
FINAL -A 23 OCTOBER 2023 
  
9.6.3.  Unscheduled Visits 
 
Unscheduled visits are those which are not required by the study protocol, but which occur due to an ocular 
intervention or a subject complaint regarding their eye.  No specific testing is required at unscheduled visits; 
rather, the investigator and/or qualified study staff w ill perform the procedures necessary to treat/evaluate the 
subject at these visits.  Clinical data from these visits  will be recorded on the relevant Unscheduled Visit 
eCRF.    
 
9.6.4.  Missed Visits 
 
Subjects who miss a scheduled visit should be contacted by site personnel to encourage the subject to return 
to clinic as soon as possible after the missed visit.  In the event a subject does not return for multiple 
consecutive examinations, site pers onnel must make a minimum of 3 documented attempts via telephone, 
email, or regular mail to contact the subject.  If the subject does not reply to any of these attempts, site 
personnel must send a letter by certified mail (with request fo r notification of delivery receipt) to the subject.  
If a subject is non-responsive to each of these follow-up attempts, he/she will be terminated from the study 
and considered lost to follow-up. 
 
9.7. Study Exit 
 
9.7.1.  Subject Termination 
 
Subjects may be terminated from the study due to: 
 
 Failure to meet protocol eligibility criteria  
 Investigator decision that termination is medically indicated 
 Voluntary withdrawal from the study 
 Lost to follow-up 
 Other administrative reasons (e.g., study te rminated by Sponsor, technical problems, non-
compliance with study medication administ ration or other study requirements, etc.) 
 
Subjects who terminate due to the occurrence of an AE  will be followed until resolution or stabilization of 
the event. 
 
Subjects who exit the study due to failure to meet el igibility criteria may be replaced.  Subjects who exit the 
study prematurely for other reasons will not be repl aced.  The Sponsor (or designee) should be promptly 
notified of a subject’s early termination, and informa tion regarding the terminati on (e.g., date and reason) 
should be documented in the source records and on the Study Exit eCRF. 
 
9.7.2.  Subject Completion 
 
Subjects will be considered to have completed the study if they did not terminate study participation prior to 
completion of primary endpoint assessment at the Treatment Visit.  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 20 OF 54 
FINAL -A 23 OCTOBER 2023 
 10. ADVERSE EVENTS 
 
Throughout the course of the study, all efforts must be made by the investigator to remain alert to possible 
AEs or untoward findings.  All AEs must be assessed fo r severity and relationship to the study drug, and the 
investigator must take all appropriate and necessary therapeutic measures required for AE resolution.  
Adverse events must be evaluated until resolution or, if the AE is assessed as chronic, until stable.   
 
10.1.  Adverse Event Definitions 
 
Most of the AE definitions provided are published in either CFR 314.80 Post Marketing Reporting of 
Adverse Drug Experiences, CFR 312.32 – IND Safety Reporting  or ICH E6 – Good Clinical Practice:  
Consolidated Guidance.   Because of the differing sources for these definitions, some terminology; e.g., 
“adverse event”, “adverse reaction”, and “adverse experi ence”, differs.  For this study, these terms should be 
considered equivalent. 
 
10.1.1.  Adverse Event (AE)  
 
Any untoward medical occurrence associated with the use of a drug in humans, whether or not considered 
drug-related.2    
 
10.1.2.  Adverse Drug Reaction (ADR)  
 
Any noxious and unintended response to a medicinal product administered at any dose.  A reasonable 
possibility must exist that the adverse reaction is  related to the medicinal product administered.3 
 
10.1.3.  Unexpected Adverse Event or Unexpected Suspected Adverse Reaction   
 
An AE or suspected adverse reaction is considered "unexpected" if it is not listed in the Package Insert 
(Appendix 2 ) or is not listed at the specificity or sev erity that has been observed; or, since an IB is not 
required, is not consistent with the risk information described in the general investigational plan or elsewhere 
in the current application, as amended.  "Unexpected," as used in this definition, also refers to AEs or 
suspected adverse reactions that are mentioned in the IB as occurring with a class of drugs or as anticipated 
from the pharmacological properties of the drug but ar e not specifically mentioned as occurring with the 
particular drug under investigation.4 
 
10.1.4.   Suspected Adverse Reaction  
 
Any AE for which there is a reasonable possibility th at the drug caused the event. For the purposes of 
Investigational New Drug (IND) safety reporting, "reasonable possibility" means ther e is evidence to suggest 
 
2 CFR 312.23 – IND Safety Reporting, 
https://www.accessdata.fda.gov/scripts/c drh/cfdocs/cfcfr/CFRS earch.cfm?fr=312.32  
3 ICH E6 – Good Clinical Practice:  Consolidated Guidance, Glossary, p 1. 
4 4 CFR 312.23 – IND Safety Reporting, 
https://www.accessdata.fda.gov/scripts/c drh/cfdocs/cfcfr/CFRS earch.cfm?fr=312.32  
 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 21 OF 54 
FINAL -A 23 OCTOBER 2023 
 a causal relationship between the study drug and the AE. Suspected adverse reaction implies a lesser degree 
of certainty about causality than adverse r eaction, which means any AE caused by a drug.5  
 
10.1.5.  Life-Threatening Adverse Event or Life -Threatening Suspected Adverse Reaction  
 
An AE or suspected adverse reaction is considered “life-th reatening” if, in the view of either the Investigator 
or Sponsor, its occurrence places the subject at immediate risk of death.  Life-threatening AEs do not include 
AEs or suspected adverse reactions that, had they o ccurred in a more severe form, might have caused death.6 
 
10.1.6.  Serious Adverse Event (SAE) or Serious Suspected Adverse Reaction 
 
An AE or  suspected adverse reaction that, in the view of eith er the Investigator or Sponsor, results in any of 
the following outcomes:  
 
 Death 
 Is life-threatening7  
 Requires in-patient hospitalization or prolongation of existing hospitalization 
 Persistent or significant disability/incapacity, mean ing there is a substantial disruption of the 
subject’s ability to conduct normal life functions 
 A congenital anomaly or birth defect 
 
Important medical events that may not result in death, be life-threatening, or require hospitalization may be 
considered serious when, based upon appropriate medical judgment, they  may jeopardize the subject and 
may require medical or surgical intervention to pr event one of the outcomes listed in this definition.8  
 
 
10.1.7.  Treatment-Emergent Adverse Event (TEAE)  
 
An AE not present prior to initiation of therapy, or an al ready present event that wor sens either in intensity or 
frequency following initiation of therapy w ill be considered Treatment-Emergent.  
  
 
5 CFR 312.23 – IND Safety Reporting, 
https://www.accessdata.fda.gov/scripts/c drh/cfdocs/cfcfr/CFRS earch.cfm?fr=312.32  
6 CFR 312.23 – IND Safety Reporting, 
https://www.accessdata.fda.gov/scripts/c drh/cfdocs/cfcfr/CFRS earch.cfm?fr=312.32  
7 A life-threatening SAE is any AE or a dverse reaction that places the subject, in the view of the Investigator, at 
immediate risk of death from  the reaction as it occurred ( i.e., it does not include a reaction that, had it occurred in a 
more severe form, might have caused death).  
8 CFR 312.23 – IND Safety Reporting, 
https://www.accessdata.fda.gov/scripts/c drh/cfdocs/cfcfr/CFRS earch.cfm?fr=312.32  
 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 22 OF 54 
FINAL -A 23 OCTOBER 2023 
  
10.2.  Adverse Event Assessment and Documentation 
 
All AEs that occur from the time the subj ect receives the first dose of study drug9 until study participation 
has been completed (e.g., TEAEs) must be documente d.  Any medical condition present prior to the first 
study drug dose that remains unchanged or improves will not  be recorded as an AE; however, a worsening of 
the condition after dosing with the study drug, will be considered an AE.   
 
Adverse events may be determined by evaluati ng the following in relation to the study subject: 
 
 Observed or volunteered problems 
 Complaints 
 Physical signs and symptoms  
 The occurrence of a medical condition during the study, which was absent at baseline 
 The worsening of a baseline medical condition during the study 
 
Treatment-emergent AEs, regardless of causal relatio nship, must be assessed by the investigator and 
recorded in the source documentation and the appropriat e eCRF.  Each AE must be described as ocular or 
non-ocular along with the following information: date of  onset, date of resolution, severity, frequency of the 
event (single episode, intermittent, con tinuous), action taken (none, medical and/or surgical), relationship to 
study drug, and seriousness criteria .  Any medication necessary for the treatment of an AE must be recorded 
on the Concomitant Medication eCRF and any surgical  intervention necessary for AE treatment must be 
recorded on the Concomitant Procedure eCRF.  If more than one distinct AE occurs, each event should be 
recorded separately. 
 
Adverse events will be documented beginning at the time of onset, and documentation must continue until 
recovery is noted.  Events that are ongoing at the tim e of study exit must be followed until resolution or 
stabilization. 
 
10.2.1.  Adverse Event Severity 
 
Adverse event severity will be assessed by the i nvestigator using the following definitions: 
 
Mild Subject is aware of sign or symptom, but it is easily tolerated  
Moderate Subject experiences discomfort enough to cause interference with 
usual activity 
Severe AE is incapacitating to subject, causi ng inability to work or do usual 
activity 
 
  
 
9 Events that occur between the Screening Visit and initial administration of study drug should be recorded as Medical 
History, and not as an AE.    
 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 23 OF 54 
FINAL -A 23 OCTOBER 2023 
  
10.2.2.  Adverse Event Relationship to Study Drug 
 
The relationship of the AE to study drug will be assessed  by the investigator usi ng the following definitions: 
 
Not Related  E v i d e n c e  e x i s t s  t h a t  t h e  A E  has a cause other than the study 
drug (e.g. pre-existing condition or underlying disease, 
intercurrent illness, or concom itant medication) and does not 
meet any other criteria listed.  
  
Possibly Related  A  t e m p o r a l  r e l a t i o n s h i p  e x i s t s  b e t w e e n  e v e n t  o n s e t  a n d  
administration of study drug.  Although the AE may appear 
unlikely to be related to the study drug, it cannot be ruled out 
with certainty; and/or the event cannot be readily explained by 
the patient’s clinical state or concomitant therapies.  
 
Probably Related  A  t e m p o r a l  r e l a t i o n s h i p  e x i s t s  b e t w e e n  t h e  e v e n t  o n s e t  a n d  
administration of study drug; it appears with some degree of 
certainty to be related based on known therapeutic and 
pharmacologic actions of the study drug.  It cannot be readily 
explained by the patient’s clin ical state or concomitant 
therapies. 
 
Definitely Related  S t r o n g  e v i d e n c e  e x i s t s  t h a t  t h e  s t u d y  d r u g  c a u s e d  t h e  A E .   
There is a temporal relationship between the event onset and 
administration of the study drug.  There is strong therapeutic 
and pharmacologic evidence that the event was caused by the 
study drug.  The patient’s clinical state and concomitant 
therapies have been ruled out as a cause.  
 
10.3.  Adverse Event Reporting 
 
Any treatment-emergent AE occurring in the study must  be reported on the AE eCRF.  Expedited reporting 
of an AE is required if the event is considered “ser ious”, regardless of relationship to the study drug or 
whether the event is expected or unexpected. 
 
  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 24 OF 54 
FINAL -A 23 OCTOBER 2023 
 10.3.1.  Expedited Adverse Event Reporting 
 
Any SAE that occurs during the study, regardless of re lationship to the study drug, or whether the event is 
expected or unexpected, must be reported to the Sponsor, or the Sponsor’s designee, within 24 hours  of the 
investigator’s becoming aware of the event.   
 
Reports should be made by completing the SAE eCRF.  Information provided on the SAE eCRF should be 
supplemented with hospitalization records, death certif icate, clinic notes from specialists evaluating the 
subject’s condition, etc. as applicable for the even t.  The urgency for reporting SAEs is 3-fold:  
 
 to facilitate discussion [and implementation, if n ecessary] by the Sponsor and the Investigator of 
appropriate follow-up measures;  
 To facilitate Investigator reporting of unanticipated  problems involving risk to human subjects to the 
IRB/EC; and  
 To enable the Sponsor to fulfill the reporting re quirements to the appropriate regulatory authority. 
 
10.4.  Device Deficiency Reporting 
 
Any adverse event directly related to the use of th e MydCombi dispenser must be documented and reported 
per the requirements listed in CFR Part A Section 80 3.10.  Reporting to the sponsor withing 24 hours of 
learning of the event as follows: 
 
 Reports of death 
 Reports of serious injury 
 
Device malfunction not related to an individual subject or that do not result in an adverse event should be 
report to the sponsor as soon as possible and include a description of the issue. 
 
11. STATISTICAL METHODS 
 
The primary objective of this study is to evaluate  the safety and efficacy of one administration of 
MydCombi, Eyenovia’s fixed combination of phenyl ephrine 2.5%-tropicamide 1% ophthalmic solution 
administered with MydCombi dispenser for dilation of the pupil.   Descriptive statistics will be employed to 
define the dilation curve for a single spray. 
 
11.1.  Efficacy Endpoints 
 
Primary Efficacy Endpoint: An efficacy analysis will be conducted to characterize a single spray of 
MydCombi: 
 
The primary performance endpoint is mean change per visit in pupil diameter at 30 minutes versus baseline, 
as measured by digital pupillometry in highly phot opic conditions.  The highly photopic condition will be 
established using a fully-charged transilluminator (muscle light) at the brightest setting.  
 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 25 OF 54 
FINAL -A 23 OCTOBER 2023 
 Additional Efficacy Analyses: 
 Proportion of eyes achieving pupil diameter of 6.0 mm or greater at 30 minutes 
 Proportion of eyes achieving pupil diameter of 7.0 mm or greater at 30 minutes 
 Mean change in pupil diameter at other timepoints (15, 60, 90, 150, 210 and 360 minutes) 
 Distribution of pupil diameters at 15, 30, 60, 90, 150, 210 and 360 minutes 
 Time from baseline to maximal pupil dilation 
 
No other formal analyses are planned.  
 
These additional efficacy readings will also be m easured using digital pupillometry in highly photopic 
conditions. 
 
11.2.  Sample Size 
 
Up to 30 subjects who have provided informed consent for study particip ation will be enrolled in the study 
and a minimum of 25 subjects will be receive study drug administration at Treatment Visit with the goal of 
having 25 subjects evaluable for the primary efficacy endpoint. The study’s sample size will provide data to 
generate descriptive statistics for the d ilation curve for 1 spray of MydCombi.   
 
11.3.  Safety Outcomes 
 
A safety analysis will be conducted to summarize the effects of a single spray of phenylephrine 2.5%-
tropicamide 1% ophthalmic solution for the following outcomes: 
 Slit-lamp examination findings 
 Occurrence of AEs 
 IOP measured at 90 minutes post-administration* 
 Visual acuity changes 
 
 
11.4.  Analysis Populations 
 
Subjects who are missing efficacy assessments at any of  the time points or are otherwise unevaluable for 
efficacy considerations will not be replaced.  
 
11.4.1.  Intent to Treat Population 
 
The intent to treat (ITT) population will consist of all subjects who received a dose of study drug.    
 
11.4.2.  Per Protocol Population 
 
The per protocol (PP) population will consist of all ITT subjects who completed all planned assessments 
without major protocol violations.   
 
 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 26 OF 54 
FINAL -A 23 OCTOBER 2023 
 11.4.3.  Safety Population 
 
The safety population will consist of all ITT subjects.   
 
11.5.  General Statistical Considerations 
 
Primary efficacy analyses will be conducted on the PP population. Safety analy ses will be performed using 
the safety analysis set. All primary analyses will be  performed in both eyes.  The pupil diameter 
measurement at each corresponding time point af ter administration will be characterized. 
Descriptive statistics will be used to summarize continuous outcomes (number of subjects [N], mean, 
standard deviation or standard error of the mean , median, maximum, and minimum) and categorical 
variables, i.e. race, sex, iris color (frequenc y and percentage) at each assessment time point.  
 
 
11.5.1.  Analysis of Primary Efficacy 
 
All time points for pupil diameter will be analyzed se parately; however, only the 30-minute time point will 
support the primary efficacy analysis.  Success is define d as drug effect resulting in ability to visualize the 
back of the eye.  A pupil size of 6 mm is consider ed adequate to visualize the back of the eye. 
 
11.5.2.  Additional Efficacy Analyses 
 
The proportion of eyes achieving pupil size of 6.0 mm or greater and 7.0 mm or greater at 30 minutes post-
dose will be summarized by eye w ith descriptive statistics.  
 
The distribution of time to maximum pupil diameter will be described by Kaplan-Meier plots.   
 
Descriptive statistics will be employed to define the dilation curve for a single spray of MydCombi. 
 
11.5.3.  Interim Analyses 
 
No interim analyses are planned for this study. 
 
11.5.4.  Analysis of Baseline Data 
 
No separate analyses of baseline da ta are planned for this study.  
 
 
  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 27 OF 54 
FINAL -A 23 OCTOBER 2023 
 12. QUALITY ASSURANCE AND QUALITY CONTROL 
 
The Sponsor or designee will perform quality control a nd quality assurance checks for this study.  Before 
initiation of study enrollment, the following documents will be reviewed with the investigator, site study 
staff, and pharmacy, as applicable:  
 
 Study protocol 
 MydCombi preparation procedures 
 MydCombi administration procedures 
 Electronic Case Report Forms (eCRF) and procedures for completion 
 Informed consent process 
 Adverse event (AE) reporting procedures 
 
12.1.  Study Monitoring 
 
During the study, the Sponsor or designee will perform periodic visits to study sites. During these visits, 
information recorded on the study eCRFs will be verified  against source documents to confirm data capture 
completeness, accuracy and logical consistency.  Stud y documents will be review ed to confirm protocol 
compliance and adherence to IRB and Sponsor-specifi ed reporting requirements, and product accountability 
will be checked.   
 
12.2.  Study Product Accountability 
 
Commercially available MydCombi will be used fo r this study. Accurate records of each MydCombi 
dispenser and medication administered must be ma intained by the Sponsor, or designee, and each study 
investigator.     Site personnel must review the shi pper at the time of kit receipt and notify the Sponsor, or 
designee, of any discrepancies.  The Sponsor, or designee, will provide an accountability log for the study 
medication.  
 
The study investigator is responsible for documenting each  MydCombi dispenser used, the date of use, the 
identifiers for subjects who received st udy drug, and the number of sprays administered to each subject eye.    
 
MydCombi product accountability will be performed by r econciling all dispensers provided to the pharmacy 
with dispensers used for study drug administration, subj ects for whom the dispenser was used, and dispensers 
returned to the Sponsor or designee.  
  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 28 OF 54 
FINAL -A 23 OCTOBER 2023 
 13. ETHICAL AND REGULATORY CONSIDERATIONS 
 
This protocol was designed and will be conducted, recorded, and reported in compliance with the principles 
of Good Clinical Practice (GCP)10.  Sponsor and Investigator respons ibilities associated with adherence to 
GCP and CFR 312 are specified in APPENDIX 4:  SPONSOR AND INVESTIGATOR OBLIGATIONS .  
The study will be performed in accordance with the recommendations guiding physicians in biomedical 
research involving human subjects adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964 
and later amendments (see APPENDIX 5:  WORLD MEDICAL ASSOCIATION DECLARATION OF 
HELSINKI ). 
 
13.1.  Institutional Review  
 
Before enrollment of study subjects, this protocol and the study-specific consent form must be reviewed and 
approved by an IRB operating in accordance with 21 CFR Part 50.  Any changes to the study protocol or 
consent forms must be approved by the IRB prior to implementation.  Materials for study patient recruitment 
and study-specific written materials provided to the subject must also be approved by the IRB prior to use.   
 
Ongoing study progress reports will be  submitted to the IRB at least annually, and more frequently if 
specified by the IRB.  Reports of safety events and any protocol deviations that affect the safety and welfare 
of a study subject will be submitted to the IRB in accordance with FDA and IRB requirements. 
 
13.2.  Informed Consent 
 
The study consent form has been developed in compli ance with 21 CFR Part 50.25.  Study consent form(s) 
must be submitted to and approved by the IRB prior to implementation.  Any IRB-requested modifications to 
the consent form must remain in compliance with 21 CFR Part 50.25. 
 
As discussed in Section 9.1 , each participant must be provided with a copy of the IRB-approved consent 
form(s) for their review, and the participants written appr oval(s) must be provided prior to initiation of study 
procedures.   
 
13.3.  Subject Confidentiality 
 
The Investigator will maintain the confidentiality of the identity of subjects enrolled in the study and the 
information contained in the study records.  The records will be made available as required for review by 
FDA and a reviewing IRB; however, to the extent possible, the subject’s identity will not be disclosed.  
 
10 Good Clinical Practice: Integrated Addendum to  ICH E6(R1) Guidance for Industry, March 2018.  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 29 OF 54 
FINAL -A 23 OCTOBER 2023 
 14. DATA HANDLING AND RECORD KEEPING 
 
Procedures for the handling and analysis of data  will be conducted using good computing practices 
meeting ICH and US FDA guidelines for the handling and analysis of data for clinical trials. 
 
14.1.  Data Quality Control and Reporting  
 
After data have been entered into the study database, a system of computerized data validation checks will 
be applied and written queries pertai ning to data omissions and discrep ancies will be forwarded to study 
sites for resolution. Study staff will update the databa se as appropriate to resolve queries generated.  All 
changes to the study data base will be documented. 
 
14.2.  Data Archiving  
 
Archived versions of the database will be saved by the Sponsor or designee consistent with ICH GCP 
Guidelines, complying with whichever of the re quirements is longer. The Sponsor will notify the 
investigator when documents should be returned. 
 
14.3.  Records Retention  
 
The Investigator’s site will retain all records relate d to the study in compliance with ICH GCP Guidelines. 
 
14.4.  Protocol Amendments  
 
Modifications to the approved protocol are only po ssible using approved protoc ol amendments and with 
the agreement of all responsible persons. The procedure for approval of a protocol amendment is identical 
to that for approval of the protocol. The IRB must be informed of all protocol amendments and should be 
asked for its opinion as to whether a full re-evalua tion of the ethical aspects of the study is necessary.  
This should be fully documented. 
 
The investigator must not implement any deviation from or change to the protocol, without discussion 
with, and agreement by the Sponsor and prior review  and documented approva l/favorable opinion of 
the amendment from the relevant IRB, except where it is necessary to eliminate an immediate hazard to 
study patients, or where the change(s) involves only logistical or administrative aspects of the study 
(e.g., change in monitor(s), change of telephone number(s)). 
 
Protocol amendments will be subm itted to the appropriate authority(ies) as required by the applicable 
regulatory requirement(s). 
  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 30 OF 54 
FINAL -A 23 OCTOBER 2023 
 15. REFERENCES 
 
 Akman A, Aydin P. Comparison of mydriatic effic acy of spray application and drop instillation of 
tropicamide 1%. Eye (Lond). 1999;13(5):653 ‒655. 
 CFR 312.23 – IND Safety Reporting, 
https://www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?fr=312.32  
 CFR 314.80 Device deficiency reporting 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cfcfr/CFRSearch.cfm?CFRPart=803&showFR=1#:~:
text=You%20must%20submit%20a %20report,or%20maintenance%20of%20one%20of 
 Farkouh A, Frigo P, Czejka M. Systemic side effect s of eye drops: a pharmacokinetic perspective. Clin 
Ophthalmol. 2016;10:2433 ‒2441. 
 Farris RL, Stuchell RN, Mandell ID. Basal and reflex human tear analysis. I Physical measurements: 
osmolarity, basal volumes, and reflex fl ow rate. Am Acad Ophthal 1981;88:852. 
 Good Clinical Practice: Integrated Addendum to  ICH E6(R1) Guidance for Industry, March 2018. 
 Grob SR, Gonzalez-Gonzalez LA, Daly MK. Manageme nt of mydriasis and pain in cataract and 
intraocular lens surgery: review of current medi cations and future direc tions. Clin Ophthalmol. 
2014;8:1281 ‒1289. doi: 10.2147/OPTH.S47569 
 Ianchulev T, Chayet A, Kahook M, Packer M, P asquale L, Weinreb RN. Ph armacodynamic profile of 
mydriatic agents delivered by ocular piezo-ej ection microdosing compared with conventional 
eyedropper. Ther Deliv. 2016;7(11):751-760. 
 Jordan A, Baum J. Basic tear flow. Does  it exist? Ophthalmol ogy. 1980 Sep;87(9):920 ‒930.Lallemand 
F, Daull P, Benita S, Buggage R, Garrigue JS. Su ccessfully improving ocular  drug delivery using the 
cationic nanoemulsion, novasorb. J Drug Deliv. 2012;2012:604204. 
 Lallemand F, Daull P, Benita S, Buggage R, Ga rrigue JS. Successfully improving ocular drug delivery 
using the cationic nanoemulsion, novasorb. J Drug Deliv. 2012;2012:604204. 
 Lynch MG, Brown RH, Goode SM, Schoenwald RD, Ch ien DS. Reduction of phenylephrine drop size in 
infants achieves equal dilation with decreased  systemic absorption. Arch Ophthalmol. 
1987;105(10):1364-5. 
 Madsen JT, Andersen KE. Phenylephrine is a frequent  cause of periorbital allergic contact dermatitis. 
Contact Dermatitis. 2015;73(1):64- 5. doi: 10.1111/cod.12394. 
 Mammo ZN, Flanagan JG, James DF, Trope GE.Generic  versus brand-name North American topical 
glaucoma drops. Can J Ophthalmol. 2012;47(1):55 ‒61. doi: 10.1016/j.jcjo.2011.12.004. 
 Merrill D L, Goldber, B, Zavell S. bis-Tropamide, A new parasympatholytic. Curr Ther Res. 
1960;12:43 ‒50. 
 Mishima S, Gasset A, Klyce SD Jr, Baum JL. Dete rmination of tear volume and tear flow. Invest. 
Ophthalmol. 5(3), 264 ‒276 (1966). 
 Petursson G, Cole R, Hanna C. Treatment of Glaucoma Using Minidrops of Clonidine. Arch 
Ophthalmol. 1984;102(8):1180-1181.  
 Ratkowsky, Evans and Alldredge, 1993. Cross-over e xperiments: design, analysis, and application  
 Scherz W, Doane MG, Dohlman CH. Tear volum e in normal eyes and keratoconjunctivitis sicca. 
Albrecht Von Graefes Arch. Klin . Exp. Ophthalmol. 1974;192(2):141 ‒150. 
 Shell JW. Pharmacokinetics of topically applied op hthalmic drugs. Surv Ophthalmol. 1982;26(4):207-18. 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 31 OF 54 
FINAL -A 23 OCTOBER 2023 
  Urtti A, Salminen L. Minimizing systemic absorption of topically administered  ophthalmic drugs. Surv. 
Ophthalmol. 37(6), 435 −456 (1993). 
 Vaajanen A, Vapaatalo H. A single drop in the eye - Effects on the whole body? Open Ophthalmol J. 
2017;11:305 ‒314. doi: 10.2174/1874364101711010305 
 Wheatcroft S, Sharma A, McAllister J. Reduction in  mydriatic drop size in premature infants. Br J 
Ophthalmol. 1993;77(6):364-5. 
 
PHENYLEPHRINE 2.5%-TROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41 VERSION A     
CONFIDENTIAL - PAGE 32 OF 54 FINAL-A 23 OCTOBER 2023   APPENDIX 1:  SCHEDULE OF MEDICATION ADMINISTRATION AND EXAMS 
  0Baseline refers to evaluations made at the Treatment Visit prior to study medication administration.  If screening and baseline are completed on the same day, the screening values may be used for baseline. 1 The completion of the administration of medication in the subject’s second eye will be considered Time 0 (T0).   2DVA to be measured using subject’s habitual correction according to office standard of practice. 3Performed using Neuroptics pupillometer – VIP 300.   4 Performed as part of slit lamp examination using investigator’s preferred method. 5 IOP to be measured using noncontact tonometer. 6 Performed using Neuroptics pupillometer – VIP 300.    7A urine pregnancy test will be conducted for females of childbearing potential 

PHENYLEPHRINE 2.5% -TROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN -MYD -TP- 41 VERSION A    
 
 33 PN-17174 -E (DCO -1152 ) APPENDIX 2:  MYDCOMBI APPROVED LABEL   
HIGHLIGHTS OF PRESCRIBING INFORMATION  
These highlights do not include all the information needed to use 
MYDCOMBI® safely and effectively. See full prescribing 
information for MYDCOMBI.  
 
MYDCOMBI (tropicamide and phenylephrine hydrochloride 
ophthalmic spray) 1%/2.5%, for topical ophthalmic use  
Initial U.S. Approval: 2023   
 
------------------- INDICATIONS AND USAGE  ------------------- 
MYDCOMBI is a combination of tropicamide, an anticholinergic, 
and phenylephrine hydrochloride, an alpha -1 adrenergic receptor 
agonist indicated to induce mydriasis for diagnostic procedures and 
in conditions where short term pupil dilation is desired ( 1) 
 
--------------- DOSAGE AND ADMINISTRATION --------------- 
Administer one metered spray to the cornea of each eye to be 
dilated. Repeat after 5 minutes. ( 2.1) 
In pediatric patients younger than 1 year old, administer one 
metered spray to the cornea of each eye to be dilated, up to a 
maximum of 3 sprays per eye per day ( 2.1) 
 
------------- DOSAGE FORMS AND STRENGTHS  ------------- 
Ophthalmic spray containing tropicamide 1% and 
phenylephrine hydrochloride 2.5%. Each metered spray 
delivers 0.008 mL which contains 0.08 mg tropicamide and 
0.2 mg phenylephrine HCl ( 3) 
 
---------------------- CONTRAINDICATIONS  ---------------------- 
Known hypersensitivity to any component of the formulation 
(4.1) 
 
--------------- WARNINGS AND PRECAUTIONS  --------------- 
Not for Injection: Topical ophthalmic use ( 5.1) 
Significant Elevations in Blood Pressure: Caution in pediatric 
patients less than 5 years of age, and in patients with 
cardiovascular disease or hyperthyroidism. In patients at 
high risk, monitor blood pressure post treatment ( 5.2) 
Central Nervous System Disturbances : Caution in pediatric 
patients where rare incidences of central nervous system 
disturbances have been reported ( 5.3) 
Intraocular Pressure : May produce a transient elevation ( 5.4) 
Rebound Miosis : Reported 1 day after administration ( 5.5)  
---------------------- ADVERSE REACTIONS  ---------------------- 
Most common ocular adverse reactions include transient 
blurred vision, reduced visual acuity, photophobia, 
superficial punctate keratitis, and mild eye discomfort. 
Increased intraocular pressure has been reported following 
the use of mydriatics ( 6.1) 
Systemic adverse reactions including dryness of the mouth, 
tachycardia, headache, allergic reactions, nausea, vomiting, 
pallor, central nervous system disturbances and muscle 
rigidity have been reported with the use of tropicamide ( 6.2) 
 
To report SUSPECTED ADVERSE REACTIONS, contact 
Eyenovia, Inc. at 1-833-393-6684  or FDA at 1 -800- FDA -1088 or 
www.fda.gov/medwatch  
 
---------------------- DRUG INTERACTIONS  ---------------------- 
Atropine -like Drugs : May exaggerate the adrenergic pressor 
response ( 7.1) 
Cholinergic Agonists and Ophthalmic Cholinesterase 
Inhibitors : May interfere with the antihypertensive action of 
carbachol, pilocarpine, or ophthalmic cholinesterase 
inhibitors ( 7.2) 
Potent Inhalation Anesthetic Agents : May potentiate 
cardiovascular depressant effects of ( 7.3) 
 
--------------- USE IN SPECIFIC POPULATIONS  --------------------- 
Pediatric Use : May rarely cause central nervous system 
disturbances which may be dangerous in pediatric patients 
(5.3, 8.4) 
 
See 15 for PATIENT COUNSELING INFORMATION  
 
 
 
 
 
 
 
 
 
Revised: 5/2023  
 
FULL PRESCRIBING INFORMATION: CONTENTS*  
1 INDICATIONS AND USAGE  
2 DOSAGE AND ADMINISTRATION  
 2.1 Recommended  Dosage  
 2.2 Administration  Instructions  
3 DOSAGE FORMS AND STRENGTHS  
4 CONTRAINDICATIONS  
 4.1 Known Hypersensitivity  
5 WARNINGS AND PRECAUTIONS  
 5.1 Topical Ophthalmic Use  
 5.2 Blood Pressure Elevation  
 5.3 Central Nervous System Disturbances  
 5.4 Intraocular Pressure  
 5.5 Rebound Miosis  
6 ADVERSE REACTIONS  
 6.1 Ocular Adverse Reactions  
 6.2 Systemic Adverse Reactions  7 DRUG INTERACTIONS  
 7.1 Agents That May Exaggerate Pressor Responses  
 7.2 Cholinergic Agonists and Ophthalmic Cholinesterase 
Inhibitors  
 7.3 Potent Inhalation Anesthetic Agents  
8 USE IN SPECIFIC POPULATIONS  
 8.1 Pregnancy  
 8.2 Lactation  
 8.4 Pediatric Use  
 8.5 Geriatric Use  
10 OVERDOSAGE  
11 DESCRIPTION  
12 CLINICAL PHARMACOLOGY  
 12.1 Mechanism of Action  
 12.2 Pharmacodynamics  
13 CLINICAL STUDIES  
14 HOW SUPPLIED/STORAGE AND HANDLING  
15 PATIENT COUNSELING INFORMATION  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
 3 4  P N - 1 7 1 7 4 - E  ( D C O - 1 1 5 2 )  
 *Sections or subsections omit ted from the full prescribing 
information are not listed.  
 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
 3 5  P N - 1 7 1 7 4 - E  ( D C O - 1 1 5 2 )  
  
FULL PRESCRIBING INFORMATION 
1 INDICATIONS AND USAGE 
MYDCOMBI (tropicamide and ph enylephrine hydrochloride ophthalm ic spray) 1% / 2.5% is 
indicated to induce mydriasis for diagnostic pr ocedures and in conditi ons where short term 
pupil dilation is desired. 
2 DOSAGE AND ADMINISTRATION 
2.1 Recommended Dosage 
Administer one metered spray to the cornea of each  eye to be dilated. Repeat after 5 minutes.  
Pediatric Patients Younger Than 1 Year Old 
In pediatric patients younger than 1 year old, administer one metered spray to the cornea of 
each eye to be dilated, up to a ma ximum of 3 sprays per eye per day. 
2.2 Administration Instructions 
The following steps should be followed sequentially: 
 
A. Load the MYDCOMBI dispenser by depr essing the FILL BUTTON at the top of 
the dispenser once. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: MYDCOMBI Dispenser Fr ont (L) and Back (R) View 
 
B. Hold MydCombi™ dispenser with thumb over Mist Butt on, wrapping other fingers 
around base.  
C. Bring MydCombi™ dispenser to patient ’s eye with Mirror facing the eye. 
- The dispenser should be as close as patient’s nose. 

PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
 3 6  P N - 1 7 1 7 4 - E  ( D C O - 1 1 5 2 )  
 - To prevent blinking, use your other hand to  gently pull lower eyelid down or ask 
patient to pull her/his lid down. 
D. Aim Mist Opening toward the center of eye. 
E. Confirm Alignment Marks (on the Fill Button and the cartridge side) align with the 
center of eye. 
- Ask patient to confirm when their eye is centered on the BLUE Mirror. 
If patient is having trouble centering their eye on the blue light, ask that they look up, 
then look at the BLUE Mirror. 
F. Firmly press and release Mist Button. 
- The drug solution should gently wet the eye. Repeat steps A to F if needed. 
G. Administer a second metered spray after 5 minutes to each dilated eye.   
H. Repeat steps A to G for the contralateral eye if it is to be dilated.  
3 DOSAGE FORMS AND STRENGTHS 
MYDCOMBI is a sterile, clear,  colorless, topical ophthalmic spray containing tropicamide 1% 
(w/w) and phenylephrine hydrochloride 2.5% (w /w). Each metered spray delivers 0.008 mL 
which contains 0.08 mg tropicamide a nd 0.2 mg phenylephrine hydrochloride. 
4 CONTRAINDICATIONS 
4.1 Known Hypersensitivity 
Contraindicated in persons showing known hypersensitivity to any component of the 
formulation. 
5 WARNINGS AND PRECAUTIONS 
5.1 Topical Ophthalmic Use  
MYDCOMBI is not indicated for injection. 
5.2 Blood Pressure Elevation 
Caution should be exercised with the use of  MYDCOMBI in pediatric patients less than 5 
years of age and patients with hyperthyroidism,  or cardiovascular dis ease. The post-treatment 
blood pressure of patients with cardiac and e ndocrine diseases and a ny patients who develop 
symptoms should be carefully monitored. 
5.3 Central Nervous System Disturbances 
Tropicamide in MYDCOMBI may cause CNS di sturbances which may be dangerous in 
pediatric patients. The possibility  of psychotic reactions and be havioral disturbances due to 
hypersensitivity to anticholinergi c drugs should be considered. 
5.4 Intraocular Pressure 
Mydriatics may produce a tr ansient elevation of intraocular pressure. 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
 3 7  P N - 1 7 1 7 4 - E  ( D C O - 1 1 5 2 )  
 5.5 Rebound Miosis 
Rebound miosis has been reported one day af ter receiving phenyl ephrine hydrochloride 
ophthalmic solution, and re-admin istration of the dr ug produced a lesser mydriatic effect. 
6 ADVERSE REACTIONS 
Because clinical trials are conducted under widely varying conditions, adverse reaction rates 
observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials 
of another drug and may not reflect the rates obs erved in practice. The most common adverse 
reactions (incidence < 2%) were  transient blurred vision, redu ced visual acuity, photophobia, 
and mild eye discomfort. 
6.1 Ocular Adverse Reactions 
Transient blurred vision, reduced  visual acuity, photophobia, superf icial punctate keratitis, and 
mild eye discomfort may occur. Increased intraocular pressure has been reported following the 
use of mydriatics. 
6.2 Systemic Adverse Reactions 
Dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, 
central nervous system disturban ces and muscle rigidity have be en reported with the use of 
tropicamide. Psychotic reactions, behavioral disturbances, and va somotor or cardiorespiratory 
collapse in children have been reported with the use of anticholinergic drugs. 
A marked increase in blood pressure has been  reported with the use of phenylephrine, 
particularly, but not limited t o, low weight premature neonate s, infants, and hypertensive 
patients. 
7 DRUG INTERACTIONS 
7.1 Agents That May Exaggerate Pressor Responses 
Phenylephrine in MYDCOMBI may enhance the pressor effects of atropine-like drugs and 
induce tachycardia in some patients. 
7.2 Cholinergic Agonists and Ophthalmic Cholinesterase Inhibitors 
Tropicamide in MYDCOMBI may interfere with  the antihypertensive action of carbachol, 
pilocarpine, or ophthalmic cholinesterase inhibitors. 
7.3 Potent Inhalation Anesthetic Agents 
Phenylephrine in MYDCOMBI may potentiate the cardiovascular depressant effects of some 
inhalation anesthetic agents. 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
 3 8  P N - 1 7 1 7 4 - E  ( D C O - 1 1 5 2 )  
 8 USE IN SPECIFIC POPULATIONS 
8.1 Pregnancy 
Risk Summary 
There are no available data on MYDCOMBI use in  pregnant women or an imals to inform any 
drug-associated risks. It is also not known whether tropicamide or phenylephrine can cause 
fetal harm when administered to a pregnant woman or can affect reproduction capacity. 
MYDCOMBI should be given to a pre gnant woman only if  clearly needed. 
8.2 Lactation 
Risk Summary 
There are no data on the presence of tropica mide or phenylephrine in  human milk from the 
administration of MYDCOMBI, the effects on th e breastfed infant, or the effects on milk 
production. The developmental and health benefits  of breastfeeding should be considered along 
with the mother’s clinical need for MYDC OMBI and any potential adverse effects on the 
breastfed child from MYDCOMBI. 
8.4 Pediatric Use 
Tropicamide in MYDCOMBI may rarely cause CN S disturbances which may be dangerous in 
pediatric patients. Psychotic reactions, be havioral disturbances, and vasomotor or 
cardiorespiratory collapse in children have been  reported with the use of anticholinergic drugs 
[see Warnings and Precautions (5.3)] .  
8.5 Geriatric Use 
No overall differences in safety  or effectiveness of MYDCOMBI  have been observed between 
patients 65 years of age and ol der and younger adult patients. 
10 OVERDOSAGE 
Overdosage of MYDCOMBI may cause a rapid ri se in blood pressure. It may also cause 
headache, anxiety, nausea and vomiting, and ventri cular arrhythmias. Prompt injection of a 
rapidly acting alpha-adrenergic blocking agent such as phentolamine has been recommended. 
11 DESCRIPTION 
MYDCOMBI is a sterile, clea r, colorless fixed dose comb ination of an anticholinergic 
(tropicamide) and an alpha-adrenergic recepto r agonist (phenylephrine hydrochloride) for 
topical ophthalmic use. The 2 ac tive ingredients are represented by the ch emical structures 
below. 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
 3 9  PN-17174-E (DCO-1152) 
 Tropicamide: 
 
Chemical Name: Benzeneacetamide, N-ethyl- α-(hydroxymethyl)-N-(4-py ridinylmethyl)- 
Molecular Formula: C 17H20N2O2 
Molecular Weight: 284.35 g/mol 
Phenylephrine Hydrochloride: 
 
Chemical Name: (R)-3-hydroxy- α[(methylamino)methyl]benzen emethanol hydrochloride 
Molecular Formula: C 9H13NO 2HCl 
Molecular Weight: 203.67 g/mol 
Each mL of MYDCOMBI ophtha lmic spray (sterile) contains : ACTIVES: Phenylephrine 
Hydrochloride 2.5% (25 mg) equivalent to 20.6 mg of phenylephrine base, Tropicamide 1% 
(10 mg); INACTIVE: Hydrochloric  Acid and/or Sodium Hydroxide may be added to adjust pH 
(pH 4.8 5.2), Water for Injection; PRESERVATIVE : Benzalkonium Chloride 0.01% (0.1 mg). 
12 CLINICAL PHARMACOLOGY 
12.1 Mechanism of Action 
Tropicamide, the anticholinergic component of  MYDCOMBI, blocks the responses of the 
sphincter muscle of the iris, dilating the pupil (mydriasis). Ph enylephrine hydrochloride, the 
alpha-1 adrenergic agonist compone nt of M YDCOMBI, act s as a mydriatic agent by 
contracting the dilator muscle of the iris. 

PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
 4 0  P N - 1 7 1 7 4 - E  ( D C O - 1 1 5 2 )  
 12.2 Pharmacodynamics 
MYDCOMBI acts in 15 to 30 minutes with maxi mal mydriasis occurring in 20 to 90 minutes. 
Darker irides tend to dilate slower than lightly  pigmented irides and to  achieve maximal effect 
may require more doses than lighter irides. 
Mydriasis will reverse spontaneously with time, with recovery after 3 to 8 hours. Complete 
recovery from mydriasis in some individuals may require 24 hours. 
13 CLINICAL STUDIES 
Two Phase 3 clinical trials were conducted to evaluate the efficacy of MYDCOMBI for 
achievement of mydriasis. The MIST-1  study was a prospective, double-masked, 
active-controlled, 3-period cross-ov er, superiority study to compare the pupil dilating effect of 
MYDCOMBI to tropicamide 1% and to phenyl ephrine 2.5%, with all solutions topically 
administered by the Optejet® Dispenser (N = 64 s ubjects; 128 eyes). The MIST-2 study was a 
prospective, multicenter, double-masked, placebo- controlled, 3-period crossover, superiority 
study to compare the pupil dilati ng effect of MYDCOMBI to plac ebo (eyewash solution), with 
both solutions topically administered by the Op tejet Dispenser (N = 70 subjects; 140 eyes). 
The primary efficacy endpoint for both studies  was the mean change in 35-minute pupil 
diameter compared to baseli ne as measured by digital pupillometry in highly photopic 
conditions. Data from the 2 studies  are presented in Table 1. At 35 minutes post-dose, the mean 
change in pupil diameter was 4.7 mm with MYDCOMBI, 4.1 mm with tropicamide, and 0.9 
mm with phenylephrine in MIST-1, and was 4.8 mm with MYDCOMBI and 0.1 mm with 
placebo in MIST-2. MYDCOMBI wa s statistically superior to tropicamide administered alone 
and phenylephrine administered alone. 
Table 1 Pupil Size and Change in Diameter from Baseline at 35 Minutes Post-Dose (MIST-1 
and MIST-2) (Per-Protocol Population [1]) 
 M I S T - 1  M I S T - 2  
Visit MYDCOMBI 
(N = 124) Tropicamide  
Alone 
(N = 124) Phenylephrine  
Alone 
(N = 124) MYDCOMBI  
(N = 138) Placebo 
(N = 
138) 
Mean Baseline (SD) 2.6 (0.05) 2.6 (0.05) 2.6 (0.05) 2.6 (0.04) 2.6 
(0.04) 
35-Minutes Post-Dose (SD) 7.3 (0.08) 6.7 (0.08) 3.5 (0.08) 7.3 (0.07) 2.7 
(0.05) 
Change from Baseline (SD) 4.7 (0.07) 4.1 (0.06) 0.9 (0.08) 4.8 (0.07) 0.1 
(0.04) 
Difference from MYDCOMBI  
(95% CI) [2] - -  0.6  
(0.4, 0.8) 3.9  
(3.7, 4.1) -- 4.7  
(4.5, 4.8) 
SD=Standard Deviation 
[1] The per-protocol (PP) population included all randomized subject s who received at least one dose of study medication and compl eted all 
planned assessments (related to the primar y endpoint) without major prot ocol violations. Two subject s in MIST-1 and one subject  in MIST-
2 who withdrew consent after their first treatment visit were not included in the PP populations which resulted in 62 completed  subjects 
(124 eyes) in MIST-1 and 69 completed subjects ( 138 eyes) in MIST-2 comprised the PP populations.  Sensitivity analysis performed on the 
intent-to-treat (ITT) population including all randomized subjects resulted in consistent efficacy results.  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
 4 1  PN-17174-E (DCO-1152) 
 [2] Treatment differences and 95% confidence interval estimates were based on a mixed model including treatment, eye, baseline dia meter, and 
carryover effect (for MIST-2 study only).  In  both studies, an unstructured covariance structure was used to account for within -subject 
correlation between eyes. 
 
MYDCOMBI provided a clinically  significant effect in the pr oportion of eyes achieving pupil 
diameter of ≥ 6 mm at 35-minute post-dose in 94% of eyes compared to 78% of eyes 
administered tropicamide alone a nd 1.6% of eyes administered phenylephrine alone, and 0% of 
eyes administered placebo. As shown in Figure 2 , peak effect was measured at the 80-minute 
evaluation when the mean change from base line was 5.2 mm. Treatme nt differences in 
mydriasis were observed as early as 20 minutes and still present at 180 minutes post-dose, the 
end of the protocol-specified observation period. 
 
Figure  2: MIST ‐1 and MIST ‐2 pooled,  mean  pupil  diameter  vs measurement  time,  by 
treatment  group.  Vertical  bars  show  95% confidence  interval  for the mean  at each  point.  
Smooth  curves  are based  on an 8 degrees  of freedom  (df) generalized  additive  model  (GAM)  
smooth  through  time,  adjusting  for baseline  pupil  diameter.  Confidence  intervals  are not 
adjusted  for correlation.  
14 HOW SUPPLIED/STORAGE AND HANDLING 
MYDCOMBI is supplied as steril e, clear, colorless solution in a 2 mL vial enclosed in a 
dispenser cartridge.  Each MYDCOMBI car tridge holds approximately 180 sprays. 

PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
 4 2  P N - 1 7 1 7 4 - E  ( D C O - 1 1 5 2 )  
 Do not tamper with or attempt to open the MYDCOMBI cartridge. Su ch action may damage 
the dispenser causing an incorr ect medication discharge volume;  additionally, the dispenser 
base may not function properly. 
Only use the MYDCOMBI cartridge with th e MYDCOMBI Dispenser base which may be 
supplied separately. The MYDC OMBI base will not work with any other cartridges. 
NDC 81046-0111-1. Carton containing one re placement sterile drug cartridge 
NDC 81046-0111-2. Box containing one  carton with one sterile dr ug cartridge, and one carton 
with one base unit 
NDC 81046-0111-5. Box containing five carton s, each with one replacement sterile drug 
cartridge 
The MYDCOMBI cartridge must be used prio r to the expiration date on the cartridge.  
Storage:  Store at room temperature 15°C to 25°C (59°F to 77°F).  
Manufactured for Eyenovia, Inc. by Alcami Corporation 
15 PATIENT COUNSELING INFORMATION 
Advise patients that they may experience sens itivity to light and bl urred vision while their 
pupils are dilated.  
Advise patients not to drive, use machinery, or  do any activity that requires clear vision until 
they are sure they can perfo rm such activities safely. 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 43 OF 54 
FINAL -A 23 OCTOBER 2023 
 
 APPENDIX 3:  EXAMINATION PROCEDURES 
 
1. Visual Acuity 
 
The evaluation of VA will be determined using the subject’s habitual refraction.    Distance VA 
measurements should be obtained at a testing dist ance of 4 meters by an optometrist, physician, or 
trained technician and according to the office standard of practice.    
 
2. Pupil Diameter Measurement 
 
Pupil diameter should be measured prior to a dditional study-specified examinations using the 
Neuroptics VIP 300 pupillometer; the same pupillome ter should be used for each evaluation on any 
study visit day for a given subject.  The subject should be asked to focus straight ahead at a target 
placed at 3 meters to avoid accommodation.  A fully- charged transilluminator, or muscle light, will be 
shone into one eye while the pupillome ter is used to measure the pupil di ameter in the fellow eye.  After 
a brief rest period, the process will be repeated to measure pupil diameter in the other eye.   
 
3. Pupillary Light Reflex 
 
Pupillary light reflex will be evaluated using a fu lly-charged transillumator, or muscle light.  The 
response will be recorded on a scale ranging from 0 (non-responsive) to 3 (brisk). 
 
4. Intraocular Pressure Measurement   
 
IOP should be taken after the slit lamp examina tion using a non-contact tonometer that does not 
require anesthetic. Recent tonometer calibration must be documented. 
 
The same tonometer should be used throughout the study. 
  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 44 OF 54 
FINAL -A 23 OCTOBER 2023 
 
 5. Slit Lamp Biomicroscopy 
 
The eyelids, conjunctiva, sclera, cornea, anterior chambe r, lens, iris and anterior vitreous of the eye will 
be examined with the aid of a table-mounted binocu lar microscope, called a slit lamp.  The patient will 
be seated during this examination and fluorescein dye should be instilled into the ocular cul-de-sac to 
facilitate the examination.  Grading will be assigned as follows: 
 
LID 
Erythema 
None (0)  Normal, without any redness, or less than mild 
Mild (+1)  A low grade flushed reddish color 
Moderate (+2) Diffused redness encompassing entire lid margin 
Severe (+3)  Deep diffused reddish color of lid margins and superior or inferior eyelid 
Edema 
None (0)  Normal, no swelling of the lid tissue, or less than mild 
Mild (+1)  Slight diffuse swelling above normal 
Moderate (+2) General swelling 
Severe (+3)  Extensive swelling of the eyelid , with/without eversion of upper or lower lids 
 
CONJUNCTIVA 
Hyperemia 
None (0) Normal.  Appears white with a small number of conjunctival blood vessels easily 
observed 
Mild (+1)  Prominent, pinkish-red color of both the bulbar and palpebral conjunctiva 
Moderate (+2) Bright, scarlet red color of the bulbar and palpebral conjunctiva 
Severe (+3) “Beefy red” with petechiae.  Dark re d bulbar and palpebral conjunctival with evidence 
of subconjunctival hemorrhage 
Edema 
None (0)  Normal, no swelling of the conjunctiva or less than mild 
Mild (+1)  Slight diffuse or regional swelling of the conjunctiva 
Moderate (+2) General swelling of the conjunctiva 
Severe (+3)  Extensive swelling of the conjunctiva 
 
SCLERA 
Normal 
Abnormal 
 
CORNEA 
Edema 
None (0)  Transparent and clear, or less than mild 
Mild (+1)  Dull glassy appearance 
Moderate (+2) Dull glassy ap pearance of epithelium with large number of vacuoles 
Severe (+3)  Stromal edema, locali zed or diffuse, with stromal striae  
 
Staining 
None (0)  No fluorescein staining of epithelium, or less than mild 
Mild (+1)  Slight punctate fluorescein staining 
Moderate (+2) Regionally dense coalescent fluorescein staining 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 45 OF 54 
FINAL -A 23 OCTOBER 2023 
 
 Severe (+3) Marked fluorescein staining with i mmediate stromal leakage as a result of epithelial 
loss 
 
 
ANTERIOR CHAMBER 
Cells 
None (0)  No cells seen, or less than mild 
Mild (+1)  + cells 
Moderate (+2) ++ cells 
Severe (+3)  +++ cells 
Hypopyon (+4) ++++ cells, hypopyon formation (ind icate hypopyon size) 
Flare 
None (0)  No Tyndall effect, or less than mild 
Mild (+1)  Tyndall beam in the AC has mild intensity 
Moderate (+2) Tyndall beam in the AC is of strong intensity 
Severe (+3)  Tyndall beam is very intensive.  Aqueous has a white, milky appearance 
 
IRIS 
Normal 
Abnormal 
 
LENS 
Lens Status 
Phakic* 
 * I n d i c a t e  Lens Opacity Grade :  None (0)  None present, or less than mild 
      M i l d  ( + 1 )  S u b t l e  
      M o d e r a t e  ( + 2 )  M o d e r a t e  
      S e v e r e  ( + 3 )  D e n s e  
Pseudophakic 
Aphakic 
 
ANTERIOR VITREOUS 
Normal 
Abnormal 
 
 
.   
  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 46 OF 54 
FINAL -A 23 OCTOBER 2023 
 
 APPENDIX 4:  SPONSOR AND INVESTIGATOR OBLIGATIONS  
 
SPONSOR OBLIGATIONS 
 
The Sponsor is committed to: 
 
1. Complying with all applicable health authority regulations governing the conduct of clinical 
research studies, including the US FDA. 
2. Protecting the rights, health, safety and welfare of study subjects. 
3. Informing clinical investigators of any new in formation about the study which may affect the 
health, safety or welfare of the subjects, or  may influence their decision to continue 
participation in the study. 
4. Providing clinical investigators with the study protocol, and CRFs on which to document the 
study evaluation variables for each subject entered into the study. 
5. Providing the statistical analysis and study report writing resources necessary to complete 
reporting of study results. 
6. Ensuring equity of consideration among all inves tigators in multicenter studies in all matters of 
publications, meeting presentations, etc. 
7. Certifying that IRB/EC approval of the protocol and Investigator Agreement will be completed 
prior to treatment at an investigational site.  
 
The Sponsor shall have the right to terminate the study at any time by written notice to the investigator .  
Without limiting this right, the Sponsor will nor mally only terminate the study under the following 
circumstances: 
 
 If severe and/or SAEs associated with the study medication in human and/or animal studies 
indicate discontinuation of the study 
 If the Sponsor wishes to discontinue the study for commercial reasons 
 If the Sponsor has reasons to believe that the study cannot be satisfactorily completed due to 
insufficient patient enrollment, or an insufficien t number of participating study sites identified 
within a reasonable time frame. 
 
  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 47 OF 54 
FINAL -A 23 OCTOBER 2023 
 
 INVESTIGATOR OBLIGATIONS 
 
Each Investigator must be either a licensed opt ometrist or licensed physician who has completed a 
residency or preceptorship in ophthalmology.  The Investigators have the following responsibilities: 
 
1. Subject Selection 
The Investigator is responsible for assuring that  all subjects entering the study conform to the 
patient selection criteria. 
 
2. Informed Consent 
The Investigator is responsible for fully reviewi ng the nature of the study, the possible risks, and 
alternative treatments with pros pective patients prior to their enrollment in the study.  The 
Investigator is responsible for obtaining written informed consent in compliance with 21 CFR 50 
for each patient, prior to enrollment in the trial.  A copy of the signed Informed Consent Form will 
be maintained in the patient's medical record. 
 
3. Institutional Review Board/Ethics Committee Approval 
The Investigator must obtain approval for particip ation in this protocol from the IRB/EC for the 
institution at which the procedure will be performed prior to entering any patients in the study.  The 
ICF to be used will also be submitted to the IRB/ EC for approval prior to initiation of the study.  
Assurance that IRB/EC approval of the study prot ocol and ICF has been obtained will be provided 
to the Sponsor, or Sponsor designee,  prior to initiation of the study. 
 
4. Subject Evaluations and Data Reporting 
The Investigator is responsible for complying with  the requirements of the study protocol and any 
amendment or clarification as published by the Spons or, or Sponsor designee.  Patient evaluations 
will be performed as described in the study prot ocol.  All information generated by the patient 
evaluation will be recorded using eCRFs with access pr ovided by the Sponsor or Sponsor designee.     
 
Investigator(s) will not deviate from the study prot ocol without prior approval of the Sponsor, or 
Sponsor designee, unless the protection of health, safety or welfare of study subjects requires 
prompt action. 
 
5. Record Retention 
The Investigator shall maintain all patient reco rds for whichever of the following periods is 
shortest: 
a. A period of 2 years after the date on which the FDA approves the marketing of the drug for the 
purpose that was the subject of the study. 
b. A period of 5 years after the date on which the r esults of the study are submitted to the FDA in 
support of the marketing of the drug for the purpose that was the subject of the study. 
 
6. Investigational Material Accountability 
The Investigator must maintain accurate records of the receipt of all investigational material 
shipped by the Sponsor, or Sponsor designee, including the date, and identification numbers of the 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 48 OF 54 
FINAL -A 23 OCTOBER 2023 
 
 product received.  In addition, accurate record s must be kept on the amount and date that 
investigational material was disp ensed or returned to the Sponsor .  The Investigator must assure 
that study supplies be dispensed only to subjects enrolled in the study per study inclusion / 
exclusion criteria and under the direct supervision of  the Investigator or his/her Co-Investigators. 
 
Records of all investigational supplies received, used  and returned must be kept by the Investigator.  
All unused investigational supplies must be return ed to the Sponsor, or Sponsor designee, as soon 
as practical upon completion of the trial.  Investig ational material accounting procedures must be 
completed before the study is considered terminated. 
  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 49 OF 54 
FINAL -A 23 OCTOBER 2023 
 
 APPENDIX 5:  WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI 
 
Ethical Principles for Medical Research Involving Human Subjects 
 
Adopted by the 18th WMA General Assembly, Hels inki, Finland, June 1964, and amended by the: 
29th WMA General Assembly, Tokyo, Japan, October 1975 
35th WMA General Assembly, Venice, Italy, October 1983 
41st WMA General Assembly, Hong Kong, September 1989 
48th WMA General Assembly, Somerset West , Republic of South Africa, October 1996 
52nd WMA General Assembly, Edin burgh, Scotland, October 2000 
53th WMA General Assembly, Washington 2002 (Not e of Clarification on paragraph 29 added) 
55th WMA General Assembly, Tokyo 2004 (Note of Clarification on Paragraph 30 added) 
59th WMA General Assembly, Seoul, October 2008 
 
A.  INTRODUCTION 
 
1.  The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement 
of ethical principles for medical research involving human subjects , including research on 
identifiable human material and data. The Declarati on is intended to be read as a whole and each of 
its constituent paragraphs should not be applied without consider ation of all other relevant 
paragraphs. 
 
2.  Although the Declaration is addressed prim arily to physicians, the WMA encourages other 
participants in medical research involvi ng human subjects to adopt these principles. 
 
3.  It is the duty of the physician to promote and safeguard the health of patients, including those who 
are involved in medical research. The physician's knowledge and conscience are dedicated to the 
fulfillment of this duty. 
 
4.  The Declaration of Geneva of the WMA binds th e physician with the words, “The health of my 
patient will be my first consideration,” and the In ternational Code of Medical Ethics declares that, 
“A physician shall act in the patient's best  interest when providing medical care.” 
 
5.  Medical progress is based on research that ultimately must include studies involving human 
subjects. Populations that are underrepresented in medical research should be provided appropriate 
access to participation in research. 
 
6.  In medical research involving human subjects, the well-being of the individual research subject 
must take precedence over all other interests. 
 
7.  The primary purpose of medical research in volving human subjects is to understand the causes, 
development and effects of diseases and improve  preventive, diagnostic and therapeutic 
interventions (methods, procedures and treatments). Even the best current interventions must be 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 50 OF 54 
FINAL -A 23 OCTOBER 2023 
 
 evaluated continually through research for their saf ety, effectiveness, e fficiency, accessibility and 
quality. 
 
8.  In medical practice and in medical res earch, most interventi ons involve risks and 
 b u r d e n s .  
 
9.  Medical research is subject to ethical standa rds that promote respect for all human subjects and 
protect their health and rights. Some research populations are particularly vulnerable and need 
special protection. These include those who cannot give or refuse consent for themselves and those 
who may be vulnerable to coercion or undue influence. 
 
10. Physicians should consider the ethical, legal and regulatory norms and standards for research 
involving human subjects in their own countries as well as applicable international norms and 
standards. No national or international ethical, legal or regulatory requirement should reduce or 
eliminate any of the protections for researc h subjects set forth in this Declaration. 
 
B.  PRINCIPLES FOR ALL MEDICAL RESEARCH 
 
11. It is the duty of physicians who participate in medical research to protect the life, health, dignity, 
integrity, right to self-determination, privacy, and confidentiality of pe rsonal information of 
research subjects. 
 
12. Medical research involving human subjects mu st conform to generally accepted scientific 
principles, be based on a thorough knowledge of the scientific literatu re, other relevant sources of 
information, and adequate laboratory and, as appr opriate, animal experimentation. The welfare of 
animals used for research must be respected. 
 
13.  Appropriate caution must be exercised in th e conduct of medical research that may harm the 
environment. 
 
14. The design and performance of each research study involving human subjects must be clearly 
described in a research protocol. The protocol should contain a statement of the ethical 
considerations involved and should indicate how th e principles in this Declaration have been 
addressed. The protocol should include informati on regarding funding, ins titutional affiliations, 
other potential conflicts of interest, incentives fo r subjects and provisions for treating and/or 
compensating subjects who are harmed as a conseque nce of participation in the research study. The 
protocol should describe arrangements for pos t-study access by study subjects to interventions 
identified as beneficial in the study or ac cess to other appropriate care or benefits. 
 
15. The research protocol must be submitted for c onsideration, comment, guidance and approval to a 
research ethics committee before the study begins . This committee must be independent of the 
researcher, the sponsor and any other undue influence.  It must take into consideration the laws and 
regulations of the country or countries in wh ich the research is to be performed as well as 
applicable international norms a nd standards but these must not be allowed to reduce or eliminate 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 51 OF 54 
FINAL -A 23 OCTOBER 2023 
 
 any of the protections for research subjects set fo rth in this Declaration. The committee must have 
the right to monitor ongoing studies. The researcher  must provide monitori ng information to the 
committee, especially information about any serious AEs. No change to the protocol may be made 
without consideration and approval by the committee. 
 
16. Medical research involving human subjects mu st be conducted only by individuals with the 
appropriate scientific training and qualifications . Research on patients or healthy volunteers 
requires the supervision of a competent and appr opriately qualified physician or other health care 
professional. The responsibility for the protection of  research subjects must always rest with the 
physician or other health care professional and neve r the research subjects, even though they have 
given consent. 
 
17. Medical research involving a disadvantaged or vu lnerable population or comm unity is only justified 
if the research is responsive to the health needs and priorities of this population or community and 
if there is a reasonable likelihood that this popul ation or community stands to benefit from the 
results of the research. 
 
18. Every medical research study involving human s ubjects must be preceded by careful assessment of 
predictable risks and burdens to the individuals  and communities involved in the research in 
comparison with foreseeable benefits to them and to other individuals or communities affected by 
the condition under investigation. 
 
19.  Every clinical trial must be registered in a publicly accessible database before recruitment of the 
first subject. 
 
20. Physicians may not participate in a resear ch study involving human subjects unless they are 
confident that the risks involved  have been adequately assessed a nd can be satisfactorily managed. 
Physicians must immediately stop a study when  the risks are found to outweigh the potential 
benefits or when there is conclusive proof of positive and beneficial results. 
 
21. Medical research involving human subjects may only be conducted if the importance of the 
objective outweighs the inherent risks and burdens to the research subjects. 
 
22. Participation by competent individuals as subject s in medical research must be voluntary. Although 
it may be appropriate to consult family members or community leaders, no competent individual 
may be enrolled in a research study unless he or she freely agrees. 
 
23. Every precaution must be taken to protect the pr ivacy of research subjects and the confidentiality of 
their personal information and to minimize the impa ct of the study on their physical, mental and 
social integrity. 
 
24. In medical research involving competent human subjects, each poten tial subject must be adequately 
informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 52 OF 54 
FINAL -A 23 OCTOBER 2023 
 
 affiliations of the researcher, the anticipated bene fits and potential risks of the study and the 
discomfort it may entail, and any other relevant aspec ts of the study. The potential subject must be 
informed of the right to refuse to participate in th e study or to withdraw consent to participate at 
any time without reprisal. Special attention should  be given to the specific information needs of 
individual potential subjects as well as to the met hods used to deliver the information. After 
ensuring that the potential subject has underst ood the information, the physician or another 
appropriately qualified individual must then seek  the potential subject’s freely-given informed 
consent, preferably in writing. If the consent cannot be expressed in writing, the non-written 
consent must be formally documented and witnessed.  
 
25. For medical research using identifiable human material or data, physicians must normally seek 
consent for the collection, analysis, storage and/or  reuse. There may be situations where consent 
would be impossible or impractical to obtain for su ch research or would pose a threat to the validity 
of the research. In such situations the research ma y be done only after consid eration and approval of 
a research ethics committee. 
 
26. When seeking informed consent for particip ation in a research study the physician should be 
particularly cautious if the potential subject is in  a dependent relationship with the physician or may 
consent under duress. In such situations the inform ed consent should be sought by an appropriately 
qualified individual who is completely independent of this relationship. 
 
27. For a potential research subject who is incompeten t, the physician must seek informed consent from 
the legally authorized representative. These indivi duals must not be included in a research study 
that has no likelihood of benefit for them unless it is intended to promote the health of the 
population represented by the potential subject, the research cannot instead be performed with 
competent persons, and the research entails  only minimal risk and minimal burden. 
 
28. When a potential research subject who is deemed  incompetent is able to give assent to decisions 
about participation in research, the physician must s eek that assent in addition to the consent of the 
legally authorized representative. The poten tial subject’s dissent should be respected. 
 
29. Research involving subjects who are physically or  mentally incapable of giving consent, for 
example, unconscious patients, may be done only if the physical or mental condition that prevents 
giving informed consent is a necessary charact eristic of the research population. In such 
circumstances the physician should seek inform ed consent from the legally authorized 
representative. If no such representative is available and if the research cannot be delayed, the study 
may proceed without informed consent provided th at the specific reasons for involving subjects 
with a condition that renders them unable to give in formed consent have been  stated in the research 
protocol and the study has been approved by a resear ch ethics committee. Consent to remain in the 
research should be obtained as soon as possible from the subject or a legally authorized 
representative. 
 
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 53 OF 54 
FINAL -A 23 OCTOBER 2023 
 
 30. Authors, editors and publishers all have ethical  obligations with regard to the publication of the 
results of research. Authors have a duty to make publicly available the results of their research on 
human subjects and are accountable for the complete ness and accuracy of their reports. They should 
adhere to accepted guidelines for ethical reporti ng. Negative and inconclusive as well as positive 
results should be published or otherwise made public ly available. Sources of funding, institutional 
affiliations and conflicts of interest  should be declared in the publication. Reports of research not in 
accordance with the principles of this Declar ation should not be accepted for publication. 
 
C.   ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH 
MEDICAL CARE 
 
31. The physician may combine medical research with me dical care only to the extent that the research 
is justified by its potential preventive, diagnostic or therapeutic value and if the physician has good 
reason to believe that participation in the research  study will not adversely affect the health of the 
patients who serve as research subjects. 
 
32. The benefits, risks, burdens a nd effectiveness of a new intervention must be tested against those of 
the best current proven intervention, except in the following circumstances: 
 The use of placebo, or no treatment, is acceptable in studies where no current proven 
intervention exists; or 
 Where for compelling and scientifically sound me thodological reasons the use of placebo is 
necessary to determine the efficacy or safety of  an intervention and the patients who receive 
placebo or no treatment will not be subject to a ny risk of serious or irreversible harm. Extreme 
care must be taken to avoid abuse of this option. 
 
33. At the conclusion of the study, patients entered in to the study are entitled to be informed about the 
outcome of the study and to share any benefits  that result from it, for example, access to 
interventions identified as beneficial in the st udy or to other appropriate care or benefits. 
 
34. The physician must fully inform the patient wh ich aspects of the care are related to the research. 
The refusal of a patient to participate in a study or the patient’s decision to withdraw from the study 
must never interfere with the patient-physician relationship. 
 
35. In the treatment of a patient, where proven interv entions do not exist or have been ineffective, the 
physician, after seeking expert advice, with in formed consent from the patient or a legally 
authorized representative, may use an unproven inte rvention if in the physician's judgment it offers 
hope of saving life, re-establishing health or allevi ating suffering. Where possible, this intervention 
should be made the object of research, designed to evaluate its safety and efficacy. In all cases, new 
information should be recorded and, wher e appropriate, made publicly available.  
PHENYLEPHRINE 2.5%-T ROPICAMIDE 1% MICRODOSE OPHTHALMIC SOLUTION  
EYENOVIA CLINICAL STUDY PROTOCOL EYN-MYD-TP-41  VERSION A    
 
CONFIDENTIAL  - PAGE 54 OF 54 
FINAL -A 23 OCTOBER 2023 
 
 PROTOCOL EYN-MYD-TP-41 
VERSION A 
 
 
A SINGLE-CENTER, OPEN LABEL, PHASE 4 STUDY OF THE SAFETY AND EFFICACY 
OF FIXED COMBINATION PHENYLEPHRINE 2.5%-TROPICAMIDE 1% OPHTHALMIC 
SOLUTION (MYDCOMBI®) ADMINISTERED WITH THE MYDCOMBI DISPENSER FOR 
PUPIL DILATION 
(THE MIST-2.1 STUDY) 
 
 
 
 
SPONSOR: 
 
EYENOVIA, INC. 
295 MADISON AVENUE, SUITE 2400 
NEW YORK NY  10017 
USA 
PHONE:  833-393-6684 
 
 
I have read this protocol in its entirety.  I agree to: 
 
 Implement and conduct this study in compliance with this study protocol; conditions of 
approval imposed by FDA and my reviewing Ins titutional Review Board (IRB); Good Clinical 
Practice (GCP); and any other app licable laws and regulations.   
 Maintain all study-related information supplie d by Eyenovia in a confidential manner.  
 
Protocol Amendment 
 
Modification of the study protocol is prohibited without prior written agreement in the form of a 
protocol amendment. All ame ndments will be created by the Sponsor and must be approved 
by the reviewing IRB prior to implementation at your  site, except when required to mitigate immediate 
safety risks or when the changes involve only logistical or administrative revisions.  
 
 
 
 
___________________________        ___________________________          ______________                       
Print Name of Investigator         Signature         Date 